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ABSTRACT OF THE DISSERTATION
Molecularly Targeted Nanoparticles for Modulation of Inflammatory Mediators in
Atherosclerosis
By
Rohun Udatta Palekar
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2015
Professor Samuel A. Wickline, Chair

The enzyme thrombin has been demonstrated through experimental and clinical studies to
play a crucial role in mediating both inflammation and thrombosis in atherosclerosis. The
cellular effects of thrombin in promoting atherosclerosis involve the activation of signaling
pathways that result in the secretion of a host of various chemokines, cytokines, cell adhesion
molecules, etc. that promote vascular inflammation. Due in part to thrombin and other proatherogenic molecules, this prolonged inflammatory state in atherosclerosis results in the
deterioration of the endothelium, increasing the risk of focal thrombosis. Current treatment
strategies to address the role of thrombin in atherosclerosis, despite efficacy of anticoagulant
activity, suffer from significant bleeding side effects. Thus, the goal of this dissertation was to
address the central role that thrombin plays in atherosclerosis and thrombosis through the
application of perfluorocarbon nanoparticles carrying the direct thrombin inhibitor Dphenylalanyl-L-prolyl-L-arginyl chloromethylketone, to impart focal anti-inflammatory and
xii

anticoagulant effects at sites of high thrombin activity. In this work, we demonstrate the ability
of thrombin-inhibiting nanoparticles and liposomes to form localized "anticlotting" surfaces that
inhibit the growth of clots both in vivo and on ex vivo applications on bare metal vascular stents.
We also investigate the use of quantitative fluorine magnetic resonance spectroscopy (19F-MRS)
to demonstrate an inverse relationship between endothelial barrier integrity and propensity for
thrombosis. We show that increased exposure of an atherosclerotic animal to an inflammatory
stimulus (e.g. cholesterol) over time decreases endothelial barrier integrity and increases
hypercoagulability, however resolution of these symptoms after removal of the inflammatory
stimulus can be tracked using 19F-MRS. Furthermore, we demonstrate through proof-of-concept
imaging studies, the possibility for non-invasive imaging of endothelial barrier disrupted
atherosclerotic plaques. These concepts in mind, our final objective was to utilize the ability to
deliver localized thrombin inhibition with thrombin-inhibiting nanoparticles and demonstrate
their ability to limit the effect of vascular inflammation on loss of endothelial barrier integrity, as
measured by 19F-MRS. Our results indicate that within one month of treatment with thrombininhibiting nanoparticles, ApoE-null atherosclerotic mice presented with diminished endothelial
barrier loss, reduced hypercoagulability, and an overall 22.5% decrease in aortic arch plaque
deposition.
Future work on this platform would involve the improvement of dosing regimens that
may address earlier time points of atherosclerosis development that may have a greater effect on
induction of vascular inflammation. Nevertheless, these results demonstrate for the first time, the
utility of focal thrombin inhibition as a means for a limiting vascular inflammation and
hypercoagulability in atherosclerosis.
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Chapter 1: Introduction

1

1.1 Atherosclerosis, Inflammation and Coagulation
Atherosclerosis and associated acute vascular syndromes represent the underlying cause
of strokes and heart attacks, which cause the greatest patient mortality in the Western world.1
Atherosclerosis is a highly inflammatory disease characterized by the development of fatty
plaques in the intimal layer of arteries. Early stages of atherosclerosis are initiated by the
accumulation of oxidized low-density lipoprotein (oxLDL) in the vessel wall, resulting in
endothelial damage that promotes the generation of thrombin as a wound healing response which
in turn, promotes the expression of cytokines and chemokines that promote the recruitment of
inflammatory cell types, e.g. monocytes and T lymphocytes. This prolonged inflammatory state
induces further thrombin generation as a response to local inflammation, establishing a feedback
loop of hypercoagulability and inflammation with thrombin playing a central role.2
1.1.1 Thrombin and Protease-Activated Receptors
The enzyme thrombin plays a central role coagulation, inflammation and atherosclerosis
and vascular pathophysiology through several pleiotropic functions. Within the coagulation
cascade, thrombin functions in converting fibrinogen into fibrin, along with various feedback
mechanisms within the coagulation cascade that amplify clot formation and thrombin generation
including activation of Factor V, Factor VIII, Factor XI and Factor XIII.
Along with its role in the coagulation cascade, thrombin has been implicated as a
powerful signaling effector through its actions on a family of G-protein coupled receptors
(GPCRs) known as protease-activated receptors (PARs), namely PAR-1. The PAR-1 receptor is
expressed on the surface of a wide range of cell types, including endothelial cells, vascular
smooth muscle cells, macrophages, and platelets among others. Thrombin exerts its effect on
2

PAR-1 (EC50 ~ 50 pM) through binding to the N-terminal extracellular domain of the receptor,
cleaving after the Arg41 residue to expose the N-terminal tethered ligand sequence SFLLRN that
subsequently activates the PAR-1 receptor and down stream signaling pathways. The effects of
PAR-1 activation on cells by thrombin has been demonstrated to be a powerful effector of
vascular physiology
Important molecular signaling events induced by thrombin and PAR-1 activation depend
in part on the NF-kB pathway. Activation of NF-kB has previously been shown to be a powerful
contributor to the progression of atherosclerotic disease, mediating the expression of various
cytokines and chemokines implicated in atherosclerosis, including but not limited to, vascular
cell adhesion molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), monocyte
chemoattractant protein 1 (MCP-1), platelet derived growth factor (PDGF) and tissue factor
(TF). Activation of NF-kB occurs upon cleavage of PAR-1 by thrombin (Fig. 1-1) followed by
signaling through G-proteins (Gαq and Gβγ) to stimulate IKK, which in turn results in the
phosphorylation and degradation of IκB, thus releasing the p65 homodimer that can then
translocate to the nucleus and facilitate the transcription of inflammatory genes.
1.1.2 The Role of the Endothelium in Homeostasis
The inflammatory state of the vasculature initiated by accumulation of oxLDL and
propagated by inflammatory mediators such as thrombin has quantifiable detrimental effects on
the endothelium. This inflamed environment promotes the formation of a dysfunctional
endothelium that is characterized by weakened or broken tight junctions that allow increased
permeability to macromolecules (such as secreted cytokines and chemokines), with further
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breakdown of the endothelial barrier through loss of endothelial cells due to apoptosis3 or
senescence4, thus predisposing patients to focal atherothrombotic events.5
Maintenance of the endothelial barrier is a normal part of homeostasis. The endothelium
serves as a natural anticoagulant barrier in its healthy state, but becomes procoagulant in the
event of endothelial dysfunction and loss of endothelial cells. In fact, endothelial cell loss as
evaluated through measurements of endothelial cells circulating in the blood has been correlated
with an increased incidence of cardiovascular disease and thrombosis. Clinical studies on
patients with coronary artery disease6, acute myocardial infarction7, and peripheral arterial
disease8 all demonstrate increased circulating endothelial cell counts associated with increased
severity of disease.
While circulating endothelial cells as a potential biomarker for endothelial damage and
atherosclerotic severity remain important avenues of research, the specificity of such
measurements is limited. An approach that might be useful to facilitate medical management of
vascular diseases would be to enable more precise identification of plaques that are at risk of
acute thrombosis, or "hypercoagulable plaques". Existing methods such as intravascular
ultrasound (IVUS), optical coherence tomography (OCT) and near-infrared spectroscopy have
all been previously used clinically to identify "at risk" plaques, however these methodologies are
largely unable to detect the >1/3 of lesions that occlude as a result of plaque erosions5 rather than
rupture of thin-capped fibrous atheromas (TCFAs).9 These erosions are largely undetectable
prior to histopathological analysis of patient samples and remain an important target for the
development of non-invasive diagnostic techniques.

4

1.1.3 Existing Strategies for Atherothrombosis Therapy
Existing antithrombotic treatments such as heparin have been effective in limiting the
activity of thrombin, as measured primarily through its inhibitory effect on coagulation.
However, the use of heparin has several limitations. First, as with many existing antithrombotic
treatments, systemically delivered heparin results in significant side effects with respect to risk of
hemorrhage and in some specific cases, development of a condition known as heparin-induced
thrombocytopenia that is characterized by the generation of antibodies against heparin-plateletfactor-4 complexes, which in turn activate platelets and induce thrombosis.10 Second, the
antithrombotic actions of heparin are largely based on its interactions with cofactors for effective
anticoagulant effect. Inhibition of thrombin (and Factors Xa, XII, XI, IX and the TF-VIIa
complex) by heparin occurs through interaction of thrombin with a complex consisting of
heparin and antithrombin III.11 One interesting drawback of heparin in its interaction with
thrombin is the ability of heparin to serve as a bridge between exosite 2 on thrombin (i.e., the
heparin binding domain) and fibrin. In this "fibrin-bound" state, the enzymatic activity of
thrombin is protected to some extent, and thus the fibrin-bound thrombin serves a potent source
of enzymatic activity that is largely not inhibited by heparin-antithrombin III complexes.12
A new class of anticoagulants known as "direct thrombin inhibitors" or DTIs has recently
gained favorability due to their improved efficacy and safety profiles. As the name implies, this
class of inhibitors aims to address the crucial role of thrombin in mediating coagulation by
directly binding to the active site, or exosites on the thrombin enzyme to inhibit its activity.
These DTIs improve upon prior anticoagulant treatments, especially regarding specificity,
because they function as inhibitors of thrombin that bind directly to the active site without the
need for a cofactor and exert inhibitory effects on both free and fibrin-bound thrombin.
5

Several direct thrombin inhibitors have been approved by the FDA for inhibiting
thrombosis in selected indications, and more recently some have been evaluated for inhibiting
the inflammatory signaling activity of thrombin in atherosclerosis. For instance, inhibitors such
as bivalirudin (Angiomax, The Medicines Company) have been approved and successfully used
for treatment of unstable angina.13 Other inhibitors such as orally administered dabigatran
(another active site inhibitor) have been approved for the prevention of stroke in patients with
atrial fibrillation along with pulmonary embolism (PE) and venous thromboembolism (VTE).14.
Recent works have also explored the utility of orally administered dabigatran15-17 as a treatment
for atherosclerosis in mice, which have demonstrated diminished plaque deposition and vascular
inflammation with continuous administration over the course of high cholesterol feeding of
ApoE knockout mice.
A notable drawback in these uses of DTIs is that the systemic administration of these
drugs results in significant bleeding tendencies. Accordingly, in the present work we propose
that the use of nanoparticles as a method of drug delivery for focal suppression of thrombin
activity would occur by concentrating the anticoagulant moieties to hypercoagulable plaque sites
and concomitantly by rapid diminution of systemic anticoagulant effects by clearance of residual
circulating nanoparticles that would improve the safety profile.
1.2 Nanotechnology for Drug Delivery and Imaging
One significant advantage of nanoparticles is their ability to serve as targeted agents for
imparting imaging contrast or drug delivery through passive targeting as a result of the enhanced
permeability and retention effect (EPR)18, or through surface modifications where nanoparticles
can be functionalized with targeting moieties (i.e. antibodies, peptides) to accomplish ligand-
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directed targeting.19,20 Additionally, surface modifications can include attachment of drugs,
imaging agents or polyethylene glycol (PEG) chains of various lengths to impart favorable tissue
half-lives. Through site-specific targeting and modulation of pharmacokinetic (PK) parameters,
highly concentrated doses of drugs and imaging agents can be delivered to a disease site with
diminished systemic side effects, offering the opportunity to accomplish increased efficacy of
imaging and therapy, as exemplified by nanoparticulate formulations of doxorubicin that have
already achieved FDA-approval for clinical use (i.e. Doxil/Caelyx).21
For effective clinical diagnostic utility, nanoparticles must be designed to achieve high
stability, selective binding, low toxicity, and favorable contrast-to-noise tissue enhancement. The
design of nanoparticles must be well controlled to allow for reproducible scale-up of synthesis
that would preserve the purity of the formulation, while maintaining uniform potency. Certain
trade-offs exist in the design of nanoparticles for effective drug delivery and imaging, where
surface functionalization to promote favorable biodistribution and PK parameters may interfere
with ligand-targeting strategies. Furthermore, sizing considerations are pertinent where deeper
penetration into affected tissues may be advantageous.22 Despite these considerations, the use of
nanoparticles as diagnostic contrast agents presents a unique opportunity to facilitate noninvasive molecular imaging of biological processes such as inflammation and thrombosis by
targeting of important pathogenic molecules.
1.2.1 Magnetic Resonance Imaging and Spectroscopy
Magnetic resonance imaging is based on the principle of the nuclear magnetic resonance
(NMR) phenomenon. When placed in a magnetic field (B0), the spins of electrons and protons in
a sample will orient themselves either parallel or antiparallel to B0, corresponding to lower or
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higher energy states, respectively. The distribution of parallel and antiparallel spins is generally
equally distributed outside of a magnetic field, resulting in a net magnetization vector of zero,
but upon encountering the B0 magnetic field, this distribution is altered, resulting in a net nonzero magnetization vector that precesses at some frequency (i.e., the Larmor frequency)
depending on the field strength of the magnet and the physical properties (i.e., the gyromagnetic
ratio) of the particular nucleus being studied. Upon external radiofrequency excitation, these
spins can absorb energy and be “tilted away” from the direction of the B0 field. After ceasing the
radiofrequency pulses, the spins then return to their original state in a process referred to as
relaxation. Using a detection coil that is tuned specifically to the Larmor frequency of the nuclei
of interest, it is possible to register the radiofrequency energy released upon return of these spins
back to equilibrium as this relaxation generates an oscillating current in the detection coil that
can then be processed and displayed as a Free Induction Decay (FID). A signature spectrum for a
compound of interest can then be generated through Fourier transform of the FID. This generated
spectrum is quantitative in that the integral of each generated peak is proportional to the number
of nuclei in the sample, and serves as the basis for the quantitative magnetic resonance
spectroscopy used in this dissertation.
By the external application of magnetic field gradients to the aligned spin system, it is
possible to encode spatial localization by altering the frequency and phase of the nuclei
contained in a sample of interest. The generation of an image is based on signal intensities in
each given voxel that in turn is affected by numerous parameters including the type of pulse
sequence/imaging parameters (repetition time, TR; echo time, TE; flip angle, etc.), that affect the
intrinsic relaxation rate of a particular sample. Signal contrast in MRI, often defined by “T1”
(spin-spin) or “T2” (spin-lattice) relaxation times, depends on the nature of the pulse sequence
8

used to excite and then measure the relaxing spins. Exogenous contrast agents may be employed
to alter local T1 or T2 relaxation times to produce highly enhanced tissue contrast as compared
to the expected background T1 or T2 signals.23
1.2.2 Fluorine Imaging and Spectroscopy with Perfluorocarbon Nanoemulsions
Fluorine magnetic resonance imaging (19F MRI) and spectroscopy (19F MRS) utilize
unique properties of fluorinated compounds that are advantageous for NMR studies over other
non-proton (1H) molecules.24 First, 19F NMR exhibits a large chemical shift range of ~300 ppm
that allows multiple fluorinated compounds to be detected simultaneously without risk of signal
overlap. The gyromagnetic ratio of fluorine nuclei is relatively close to that of 1H (42.57 MHz/T
vs. 40.07 MHz/T respectively). This 6% difference along with a relative sensitivity of 0.83 is
favorable, as the MRI signal for fluorine would be the most sensitive of all non-proton molecules
used for MRI.25 Furthermore, the use of fluorinated compounds for MRI/MRS as exogenous
contrast agents in biologic tissue offers the considerable advantage of virtually zero background
signal thereby markedly enhancing conspicuity of the contrast agent whose signature is unique as
compared with that of water protons. Thus, these properties make fluorine an attractive candidate
for quantitative molecular imaging.
Our lab has pioneered the development of fluorinated nanoparticles as ultrasound26,27 and
MRI contrast agents.28-30 These nanoparticles consist of a perfluorocarbon (PFC) core
surrounded by a stabilizing lipid-surfactant monolayer, resulting in nanoparticles ranging in
diameter from 200-250 nm (Fig. 1-2A). The outer lipid shell can be functionalized with drugs,
targeting, or imaging agents through covalent conjugation31,32 or insertion of compounds into the
membrane.33-37
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In addition to varying the type of targeting agents, it is possible to substitute a variety of
perfluorocarbon cores, with differing spectral signatures. Perfluorocarbon molecules consist
primarily of hydrocarbons that can be fluorinated by complete substitution of hydrogen atoms
with fluorine atoms. Numerous such fluorocarbons exist, and two are routinely used in our
laboratory for diagnostic imaging and spectroscopy, namely perfluoro-15-crown-5 ether (PFCE,
C10F20O5) and perfluorooctylbromide (PFOB, CF3-(CF2)6-CF2Br). The characteristic spectrum
for PFOB consists of 8 distinct peaks, which contrasts with the single peak spectrum for PFCE.
The presence of a single peak for PFCE makes it an ideal candidate for spectroscopy and
imaging as signal to noise ratio is greatly improved over that of PFOB due to the total measured
energy being confined to a single peak rather than being split into multiple peaks that are more
challenging to register simultaneously. As previously discussed, the large chemical shift range
of fluorine allows for the detection of multiple fluorinated compounds without signal overlap and
as such, detection of PFCE nanoparticles and PFOB nanoparticles is possible in the same sample
(Fig. 1-2B), as demonstrated by Morawski et al.38 Furthermore, because the relative 19F
spectroscopic signal is proportional to the amount of perfluorocarbon emulsion in a sample (Fig.
1-2C), concentration maps of targeted perfluorocarbon nanoparticles can be generated, allowing
for quantitative monitoring of molecular processes based on estimation of the number of binding
sites occupied by the nanoparticles. (Fig. 1-2D-F).
1.2.3 Advantages and Disadvantages of Perfluorocarbon Nanoparticles
PFC nanoparticles exhibit minimal toxicity and favorable biocompatibility. One early use
of perfluorocarbons in clinical medicine was as an artificial blood replacement, which
recognized their ability to dissolve and carry oxygen, with some formulations having reached
FDA approval in the past.39 Adverse effects of perfluorocarbons is very low, due in part to the
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extremely high in vivo tolerance of administrated PFCs, with an LD50 ranging from 30-41g
PFC/kg body weight. Symptoms of toxicity are relatively mild as well, characterized by “flulike” symptoms, with resolution within 12 hours. In the case of circulating PFC nanoparticles for
molecular imaging or therapy, those not bound to a specific target rapidly accumulate in the liver
and spleen, with detection possible after several minutes post-injection40 and up to 24 hours.
Subsequently, the lipid components are recycled by various plasma carriers30 and the
perfluorocarbons are exhaled through the lungs and cleared via the reticuloendothelial system.25
It is important to note the role of species differences in the secretion and clearance of large
nanoparticles especially as they relate to rodent PK models, as these differences can affect
interpretation of clearance data.40 Furthermore, the tissue half-lives of perfluorocarbons in vivo
must be considered and potentially corrected for in instances of serial imaging where long tissue
residence times 41 (i.e. PFOB) could complicate imaging studies.
1.3 Applications of Nanotechnology for Cardiovascular Imaging and Drug Delivery
Nanoparticle applications for cardiovascular imaging and drug delivery are varied based
on specific disease targets. Here we will review selected major targets of nanoparticles as they
relate to atherosclerosis, with a focus on perfluorocarbon nanoparticle-based treatments.
1.3.1 Thrombosis
Acute onset of occlusive thrombosis is the proximate cause of mortality in cases of heart
attack and stroke. Accordingly, numerous studies have examined the deployment of
nanoparticle-based imaging contrast agents for detection of thrombi. Destabilization of plaques
due to rupture or erosion can result in disruption of the normal hemostatic barrier of the
endothelium, resulting in the initiation of the coagulation cascade, which in turn generates
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thrombin and other coagulation factors, facilitating fibrin deposition and platelet activation.42
The ability to image thrombi noninvasively offers important clinical diagnostic information and
bears implications for therapeutic management of acute ischemic syndromes.43 Although
methods exist to characterize certain aspects of thrombi (e.g. thrombus age44, methemoglobin
content45, among others), the potential to image specific molecular epitopes associated with
thrombi could allow for improved localization of emerging thrombi and subsequent responses to
therapies designed to inhibit thrombotic activity.46
In 1997, Lanza et al. reported fibrin as a target for nanoparticle-based molecular imaging
of clots with the use of MRI, and described a novel paramagnetic, nanoparticle based contrast
agent targeting fibrin for T1-weighted imaging of clots. The nanoparticle used in this study was a
perfluorocarbon nanoparticle laced with various concentrations of Gd-DTPA, and conjugated to
a fibrin specific antibody NIB 1H10 that was highly specific for fibrin.28 Initial work
demonstrated the utility of these Gd-loaded PFC nanoparticles for T1-weighted imaging of
plasma clots in vitro at 4.7T 47,48. Later work confirmed direct binding of nanoparticles to fibrin
with scanning electron microscopy (Fig. 1-3A-B), and demonstrated the ability to image fibrin
bound nanoparticles both in ex vivo human endarterectomy samples at 4.7T (Fig. 1-3C), and in
vivo using a clinical 1.5T MRI scanner (Fig. 1-3D-E). 31 Additionally, Morawski et al. quantified
thrombin binding with the use of 19F MRI in human carotid endarterectomy specimens that
employed fibrin-targeted PFC nanoparticles.38
Recent work from Myerson et al. demonstrated the potential of the perfluorocarbon
nanoparticle platform for imaging and treating developing thrombi. In this work, perfluorocarbon
nanoparticles were conjugated to a direct thrombin inhibitor, D-phenylalanyl-L-prolyl-L-arginylchloromethylketone (PPACK) and delivered in vivo in a mouse model of acute thrombosis in the
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carotid artery. Ex vivo 19F MRI at 11.7T illustrated the ability of these PPACK nanoparticles to
selectively bind to the surface of thrombin-bearing clots, allowing for imaging of areas of high
thrombin activity (Fig. 1-3F-H).32 This anti-thrombin nanoparticle platform has since been
modified to include FDA-approved bivalirudin as the thrombin-binding epitope, which increases
the specificity for thrombin over and above that of PPACK.49
A perfluorocarbon nanoparticle system utilizing direct thrombin inhibitors (PPACK32 and
Bivalirudin49) not only enables imaging of active thrombi as previously discussed, but
simultaneously effects a potent localized antithrombotic property at sites of acute and active
clotting with minimal systemic side effects. The same mechanism of thrombin binding that
allows for successful imaging of clots with fluorine MRI establishes an dense “anticlotting
surface” where single nanoparticles presenting thousands of inhibitor molecules lay down in a
monolayer over the active thrombus and further inhibit the activity of clot-bound thrombin. This
effect has been observed for both PPACK and bivalirudin perfluorocarbon nanoparticles; and
extension of the system to liposomal analogues of this system explored in Chapter 2 of this
thesis. This propensity of rapid targeting of acute thrombi also suggests the potential for
thrombolytic therapy with nanoparticles. For example, Marsh et al. employed fibrin targeting of
streptokinase-loaded perfluorocarbon nanoparticles to induce rapid clot dissolution within 60
minutes of treatment, as tracked by ultrasound imaging.50,51
Other relevant applications of perfluorocarbon nanoparticles broadly related to
thrombosis pertain to acute ischemic kidney injury in which compromised microvascular blood
flow leads to death of proximal tubular cells and renal failure. For example, Hu et al.
demonstrated the utility of perfluorocarbon nanoparticles in assessing the extent of perfusion in
the renal microvasculature following acute kidney injury.52 Furthermore, recent work by Chen &
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Vemuri, et al. demonstrated the ability of the aforementioned thrombin-inhibiting nanoparticles
to limit kidney damage following ischemia/reperfusion injury by preventing clotting and
maintaining renal blood flow.53 Perfluorocarbon nanoparticles may be a particularly useful tool
for imaging applications in the kidney as contrasted with conventional gadolinium-based agents
in the evaluation of renal compromised patients, because perfluorocarbon nanoparticles are not
cleared through the kidney, but rather through the liver and spleen. Additionally, perfluorocarbon
nanoparticles do not suffer the complications from nephrogenic systemic fibrosis that restrict the
use of gadolinium agents in situations of existing renal dysfunction.
1.3.2 Endothelial Permeability and Neovasculature
Zhang et al. reported the ability of non-targeted perfluorocarbon nanoparticles to depict
endothelial damage caused by a high cholesterol diet in a fat-fed rabbit model of atherosclerosis.
The passive diffusion of these nanoparticles through disrupted endothelial barriers in vivo was
quantified with 19F MRS, where the concentration of detected nanoparticles in aortic plaques was
increased in rabbits fed a high-cholesterol diet for 7-14 months compared to minimal deposition
in plaques of rabbits fed cholesterol for only 3 months. In this study, imaging of nanoparticles
retained in endothelium-disrupted intimal plaques was demonstrated with ex vivo 19F MRI at
11.7T (Fig. 1-4A-B).54
Perfluorocarbon nanoparticles have also been used to track endothelial progenitor cells as
demonstrated by Partlow et al.55 In this work, perfluorocarbon nanoparticle-labeled
stem/progenitor cells acquired from cord blood samples after fetal delivery can be tracked to
tumor neovasculature and quantified in vivo with 19F MRI/MRS. Other groups have
demonstrated the utility of perfluorocarbon emulsions for the tracking stem cells in vivo further
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demonstrating the potential of fluorine imaging for non-invasive evaluation of tissue
regenerative strategies.56,57
Other studies have focused on depiction of neovasculature in atherosclerotic plaques.
Taking advantage of the “leaky” nature of developing vasculature, several albumin-binding
paramagnetic agents have been utilized for imaging of permeable neovasculature. Cornily et al.
evaluated the use of gadocoletic acid trisodium salt, or “B-22956/1” which binds with high
affinity to albumin, and evaluated its use in atherosclerotic rabbits. They demonstrated the ability
of their albumin-binding agent to produce increased enhancement of plaques over and above
enhancement produced by Gd-DTPA alone, using T1-weighted MR sequences.58 More recent
work by Phinikaridou et al. involved the use of gadofosveset, a clinically approved albuminbinding T1 MRI agent for the evaluation of permeable endothelium in plaques59 and the tracking
of interventional therapies (minocycline, ebselen) in reducing plaque burden.60
Winter et al. first demonstrated the use of a targeted T1 agent using Gd-loaded
perfluorocarbon nanoparticles targeted to the αvβ3 integrin that is associated with plaque
neovasculature. This study showed the potential for in vivo assessment of angiogenesis and
neovasculature development using a 1.5T clinical MR scanner (Fig. 1-4C).61 Targeting of the
αvβ3 integrin also enables therapeutic applications of nanoparticles such as the focal inhibition of
angiogenesis that is critical for plaque growth62, by targeting the αvβ3 integrin that is highly
expressed in neovasculature. In this study, αvβ3-targeted perfluorocarbon nanoparticles were
loaded with an anti-angiogenic agent (fumagillin) and tested for efficacy in atherosclerotic
rabbits. Administration of fumagillin-loaded αvβ3-targeted perfluorocarbon nanoparticles resulted
in a reduction of plaque neovasculature by 50-75% following a single pulsed dose, with a
sustained effect for up to 3 weeks following initial therapy.63 Additionally,, molecular targeting
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of nanoparticles to αvβ3 integrins has allowed for the tracking of anti-angiogenic therapy in the
treatment of peripheral vascular disease using MRI as a readout.64
Targeting of the αvβ3 integrin also has proven therapuetic utility in animal models of
restenosis as shown by Cyrus et al. with local catheter delivery of rapamycin-loaded αvβ3targeted nanoparticles that inhibited restenosis following balloon overstretch injury in rabbits
without the need for stenting.35 In this study, the inhibition of restenosis was observed only for
integrin-targeted delivery of the drug-loaded nanoparticle, but statistically insignificant for the
non-targeted version of the drug loaded nanoparticle. The targeting and retention of
nanoparticles allowed for site specific delivery of rapamycin through “contact-facilitated drug
delivery”65, while the addition of gadolinium on the nanoparticle surface allowed for effective
T1-weighted imaging of drug delivery to the treatment area.
1.3.3 Inflammatory Mediators
The role of inflammation in atherosclerosis has been recognized with markers of
inflammation being investigated as potential targets for therapeutic intervention.66 The early
phases of atherosclerosis involve the attachment and recruitment of inflammatory immune
effector cells (e.g., monocytes), which contribute to plaque development. The mechanism of
inflammatory cell recruitment involves the expression of cellular adhesion molecules on the
inflamed endothelium, such as vascular cell adhesion molecule (VCAM-1), intracellular
adhesion molecule (ICAM-1) or P-selectin, among others.2
Fluorine imaging also has been utilized to image VCAM-1 upregulation in
atherosclerosis, with the use of PFC nanoparticles as carriers for VCAM-1 targeting peptides
previously developed by Kelly et al.67 Initial work in this area was accomplished by Southworth
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and Kaneda, et al. using this anti-VCAM-1 nanoparticle for the imaging of renal inflammation in
hyperlipidemic mice, demonstrating significant amounts of VCAM-1 targeted nanoparticles in
inflamed kidneys from fat-fed ApoE null mice as compared to minimal deposition in kidneys of
control wild-type mice (Fig. 1-5A-C).68 Pan et al. extended this functionality by designing a
novel linker system for rapidly post-formulation functionalization of lipidic (and PFC)
nanoparticles. In this work, VCAM-1 targeting peptides were linked to a membrane inserting
peptide based on the amphipathic cationic peptide melittin, that enabled rapid insertion of a
VCAM targeting peptide into the perfluorocarbon nanoparticle surfactant membrane in a simple
mixing procedure. These VCAM-1 targeted nanoparticles were utilized in the ApoE null model
of atherosclerosis, where VCAM-1 targeted particles were preferentially detected in the aortas of
ApoE null mice as compared to minimal signal from aortas from wild-type mice (Fig. 1-5D).69
1.4 Conclusions
The therapeutic and diagnostic techniques used to identify and treat atherosclerosis
should address not just the late clinical presentations of atherosclerosis (plaque rupture, erosions,
thrombosis), but also should be poised to identify early indicators such as vessel
hypercoagulability and inflammation, with a goal to apply and direct therapies to protect vascular
endothelial function. How focal inhibition of thrombin might alter the course of disease
progression in atherosclerotic subjects remains unknown. For our purposes, we ask specifically
can focal thrombin inhibition limit the detrimental effects of a diet-induced inflammatory state
on endothelial health and plaque procoagulant activity, while limiting systemic side effects that
are characteristic of conventional anticoagulants? Accordingly, the goal of this dissertation is to
examine the utility of nanoparticle-based approaches for quantifying endothelial barrier integrity
and plaque thrombotic risk, and evaluate the use of nanoparticles for focal administration of
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thrombin inhibitors to limit the procoagulant and proinflammatory effects of thrombin in
atherosclerotic mice. We address these objectives in the following chapters:
•

CHAPTER 2: Characterize the ability of thrombin-inhibiting liposomes to provide local
anti-clotting activity through the generation of clot-inhibiting surfaces on damaged and
thrombosed arteries.

•

CHAPTER 3: Demonstrate the utility of thrombin-inhibiting perfluorocarbon
nanoparticles in forming anti-clotting surfaces on bare metal stents in preventing
thrombosis.

•

CHAPTER 4: Evaluate changes in endothelial barrier integrity in response to
proatherogenic diet and elucidate the relationship of endothelial barrier integrity to
hypercoagulability in atherosclerotic mice with the use of perfluorocarbon nanoparticles

•

CHAPTER 5: Demonstrate the effect of thrombin-inhibiting perfluorocarbon
nanoparticles on preserving endothelial barrier integrity and limiting vessel procoagulant
and proinflammatory activity in atherosclerotic mice
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Figure 1-1

Figure 1-1: Activation of the NF-kB pathway by thrombin. Thrombin cleavage of PAR-1
stimulates IKK, followed by dissociation and degradation of IkB from the IkB-p65 complex. The
p65-homodimer is then phosphorylated and facilitates transcription of inflammatory genes that
promote atherosclerosis
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Figure 1-2

Figure 1-2: (A) Schematic of perfluorocarbon nanoparticles. (B) Sample fluorine (19F) spectra
demonstrating unique signatures of two types of perfluorocarbon nanoparticles—perfluoro-15crown-5 ether (PFCE) and perfluorooctylbromide (PFOB). (C) Fluorine signal measured using
19

F magnetic resonance spectroscopy (19F-MRS) is proportional to the volume of

perfluorocarbon in a sample. Using this observation, it is possible take samples such as a (D)
human endarterectomy specimens and (E) image deposited nanoparticles with 19F-MRI to
generate a (F) concentration map to locate differential deposition of nanoparticles within a
sample. (Reprinted with permissions from 38)
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Figure 1-3

Figure 1-3: Imaging with thrombus-specific nanoparticles. Scanning electron micrographs depict
fibrin clot (A) without nanoparticle treatment, with arrows depicting fibrin fibrils and (B) with
addition of fibrin-targeted perfluorocarbon nanoparticles, with arrows depicting fibrin-bound
nanoparticles. (C) T1-weighted gradient echo images of human carotid endarterectomy
specimens treated with fibrin-targeted nanoparticles (left) demonstrating contrast enhancement
with nanoparticle treatment compared to control (right). (D) In vivo demonstration of T1weighted contrast enhancement at thrombus site with fibrin-targeted nanoparticles compared
with (E) control thrombus in the contralateral external canine jugular vein (Reprinted with
22

permission from 31) (F-H) Ex vivo 19F imaging at 11.7T of thrombin-targeted PFC nanoparticles
bound to mouse thrombi. (F) Proton scan of excised mouse carotid artery with occlusive
thrombus, with (G) overlay of 19F MR image collected in (H). (Reprinted with permission from
)
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Figure 1-4

Figure 1-4: Imaging of endothelial permeability and neovasculature. (A) Sagittal 3D rendering of
nanoparticle deposition measured at 11.7T in a rabbit aorta excised following 12 months of
cholesterol feeding and 12 hours of nanoparticle circulation in vivo. (B) Cross sectional 19F
image of nanoparticle deposition in atherosclerotic plaque. Concentration mapping illustrates
depth of penetration and local concentration in the rabbit atherosclerotic plaque following 9
months of cholesterol feeding and 2 hours of in vivo nanoparticle circulation. (Reprinted with
permission from 54) (C) Localization of αvβ3-targeted nanoparticles to areas of plaque
angiogenesis in atherosclerotic rabbits. Top panel shows region of interest, with cross sectional
images of aorta prior to administration of nanoparticles (Pre), following nanoparticle
administration (Post), and the application of a segmented aortic wall mask (Segmented) used to
quantify T1-weighted contrast enhancement (Enhancement). (Reprinted with permission from 61)
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Figure 1-5

Figure 1-5: Imaging of Inflammatory Mediators. Ex vivo 19F MRI of atherosclerotic mouse
kidneys (top row) or wild-type mouse kidneys (bottom row) with (A) proton scan for anatomical
detail, (B) 19F image, and (C) overlay of 19F image on proton image demonstrating increased
accumulation of VCAM-1 targeted PFC-nanoparticles in atherosclerotic kidneys over wild-type
kidneys, corresponding to differences in VCAM-1 expression in atherosclerotic vs. wild-type
subjects. (Reprinted with permission from 68) (D) Targeting of PFC-nanoparticles using VCAM-1
targeting peptides increases binding of nanoparticles in atherosclerotic mouse aortas, as
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measured with 19F magnetic resonance spectroscopy at 11.7T. (Reprinted with permission from
)
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Chapter 2: Generation of Sustained Anticlotting Barriers
with Thrombin-Targeted Liposomes
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Chapter Overview
The goal of the present work was to design and test an acute-use nanoparticle-based
antithrombotic agent that exhibits sustained local inhibition of thrombin without requiring a
systemic anticoagulant effect to function against acute arterial thrombosis. To demonstrate proof
of concept, we functionalized the surface of liposomes with multiple copies of the direct
thrombin inhibitor, D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone (PPACK), which
exhibits high affinity for thrombin as a free agent, but manifests too rapid clearance in vivo to be
effective alone. The PPACK-Liposomes were formulated as single unilamellar vesicles, with a
diameter of 170.78 ± 10.59 nm and a near neutral charge. In vitro models confirmed the
inhibitory activity of PPACK-Liposomes, demonstrating a K !' of 172.6 nM. In experimental clots
in vitro, treatment of formed clots completely abrogated any further clotting upon exposure to
human plasma. The liposomes were evaluated in vivo in a model of photochemical-induced
carotid artery injury, resulting in significantly prolonged arterial occlusion time over that of
controls (69.06 ± 5.65 min for saline treatment, N=6, 71.33 ± 9.46 min for free PPACK treated;
N=4, 85.75 ± 18.24 min for precursor liposomes; N=4, 139.75 ± 20.46 min for PPACKLiposomes; P = 0.0049, N=6). Systemic anticoagulant profiles revealed a rapid return to control
levels within 50 minutes, while still maintaining antithrombin activity at the injury site. The
establishment of a potent and long-acting anticoagulant surface over a newly forming clot with
the use of thrombin targeted nanoparticles that do not require systemic anticoagulation to be
effective offers an alternative site-targeted approach to the management of acute thrombosis.

36

2.1 Introduction
The development of new pharmaceutical agents to treat acute arterial thrombosis remains
a subject of active investigation to meet the continuing medical need for safe and controllable but
powerful anticoagulation.1-3 The deployment of direct thrombin inhibitors such as dabigatran
recognizes the central role that thrombin plays in clot formation by proteolytic cleavage of
fibrinogen into fibrin, but also its role in activation of platelets and Factor XIIIa, among others.4,5
Many of these treatment options display small therapeutic windows, with concerns for
deleterious side effects such as bleeding that hamper their clinical adoption.4-7
Previous studies have suggested the potential of nano-scaled drug delivery systems as
antithrombotic agents.8-11 Such treatments would allow for effective, highly localized
antithrombotic activity with potentially fewer risks for systemic side effects. Of these candidate
nanoscale constructs, liposomes offer many advantages, including their biocompatibility and
biodegradability with a history of suitability for regulatory approval.12-14 Indeed, liposomes
already have achieved clinical translation through the recent labeling of a number of FDAapproved formulations (e.g., Doxil, DaunoXome, DepotDur, Ambisome). Moreover, the
potential for encapsulation of drugs within liposomes together with surface conjugation of
anticoagulant agents offers a design format that could enable synergistic combination therapy.15
Herein, we describe an antithrombotic agent formed through the conjugation of direct
thrombin inhibitors to the surface of unilamellar liposomes. The use of a direct thrombin
inhibitor conjugated to the surface of the liposome would allow for high affinity and avidity
binding and targeting to thrombin at the site of acute thrombosis. Furthermore, we postulated that
the construct would remain active at the site of acute thrombosis for hours by forming an
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anticlotting surface after binding, while manifesting only a very transient systemic anticoagulant
effect, which should mitigate the potential for hemorrhage without the need for an antidote. For
proof of concept, the inhibitor used in this study is a short chain peptide, D-phenylalanyl-Lprolyl-L-arginyl-chloromethyl ketone (PPACK), which inhibits thrombin through alkylation of a
histidine residue at the active site.16
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2.2 Materials and Methods
2.2.1 Liposome Preparation
Unilamellar liposomes were created using standard protocols as previously described.17 A
lipid mixture containing 94 mol% egg phosphotidylcholine, EPC (Lipoid, Newark, NJ), 4 mol%
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, DPPE (Avanti Polar Lipids, Alabaster, AL),
and 2 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)2000], DSPE-PEG-COOH (Avanti Polar Lipids, Alabaster, AL) was dissolved in chloroform.
For fluorescent liposomes, the lipid mixture contained 93.9 mol% EPC, 4 mol% DPPE, 2 mol%
DSPE-PEG-COOH, and 0.1 mol% 1,1’-Dioctadecyl-3,3,3’,3’-Tetramethylindocarbocyanine
Perchlorate, DiI (Invitrogen, Carlsbad, CA).18 The lipid mixture at 10 mg/ml was placed in a
heated water bath and dried into a film using rotary evaporation. The resulting lipid film was
further dried in a vacuum oven at 40˚C overnight to ensure complete evaporation of any residual
organic solvent.
After drying, the lipid film was hydrated in phosphate buffered saline (WashU Tissue
Culture Lab, St. Louis, MO) and sonicated at level two on a Branson probe sonicator for 2
minutes to resuspend the lipids and generate multilamellar vesicles (MLVs). The MLVs were
subjected to extrusion through stacked polycarbonate/polyethylene filters (Whatman Inc,
Piscataway, NJ) with a pore size of ~200 nm to generate a suspension of PEGylated, carboxyterminated unilamellar liposomes.
2.2.2 PPACK-Liposome Formulation
PPACK conjugation was accomplished using amine-carboxyl coupling. Activation of
carboxyl groups was accomplished using EDCI, 1-ethyl-3-(3-dimethylaminopropyl)
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carbodiimide HCl (Pierce, Rockford, IL), added in excess at 2 mg/ml to the suspension of
carboxy-terminated liposomes and mixed for 15 minutes. PPACK (American Peptide Company,
Sunnyvale, CA) was added to the activated precursor liposomes at 12.5 mg/ml and allowed to
mix overnight. Excess EDCI and uncoupled PPACK was removed from the suspension using
dialysis tubing of MWCO 3000-5000 (Spectrum Labs, Rancho Dominguez, CA) and allowed to
filter for four hours.
2.2.3 Liposome Characterization
The sizes of the liposomes with or without PPACK incorporated were analyzed by
dynamic light scattering (Brookhaven Instruments Corp., Holtsville, NY). Zeta potential values
were determined with a PALS Zeta Potential Analyzer (Brookhaven Instruments Corp.,
Holtsville, NY). Liposomes were diluted in MilliQ Water for zeta potential measurements. Data
was acquired in the phase-analysis light scattering mode following solution equilibration at 25˚C.
For transmission electron microscopy evaluation of liposomes, samples of precursor and
PPACK-liposomes were deposited onto formvar-coated Cu grids, followed by application of the
vanadium-based NanoVan negative stain (Nanoprobes, Yaphank, NY). The liposomes were
visualized using an FEI Spirit TEM at 120 kV.
Conjugation of PPACK to precursor liposomes was confirmed through RP-HPLC
quantification of uncoupled PPACK recovered from the supernatant after centrifugation of predialysis PPACK-Liposomes mixed with Cleanascite lipid adsorption reagent (Biotech Support
Group, Monmouth, NJ). PPACK elution was accomplished using a C18 reverse phase column
(Grace, Deerfield, IL) on a Waters HPLC system. Eluent A was 0.1% Trifluoroacetate (TFA) in
water, Eluent B was 0.1% TFA in acetonitrile, and a linear gradient (10-30% B) was established
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over 20 minutes. PPACK elution was measured at a wavelength of 215 nm. Determination of the
liposomal PPACK concentration was accomplished through mass balance of uncoupled PPACK
subtracted from total PPACK added during the conjugation step.
The Stewart assay19 was employed to determine liposome concentration through the
measurement of total phospholipid content of the liposome sample. For the phospholipid content
measurements, 100 µl of liposomes was diluted up to 2 ml with chloroform, followed by addition
of 2 ml 0.1 M ammonium ferrothiocyanate. The mixture was vortexed for 1 min, and the organic
phase was removed and measured at 488 nm using a Shimadzu UV-1601 UV-Vis
spectrophotometer (Shimadzu Scientific Instruments, Columbia, MD). The results were plotted
against a standard curve of known lipid concentrations to determine liposomal phospholipid
concentration. From this data, given the size of the liposome, liposome concentration was
calculated accordingly.
2.2.4 In Vitro Inhibition of Thrombin Activity
A Chromozym TH, Tosyl-Gly-Pro-Arg-4-nitranilide acetate (Roche Applied Science,
Indianapolis, IN) assay was utilized to quantify PPACK-mediated inhibition of thrombin in
accordance with existing methods.20 Varying amounts of free PPACK or PPACK-Liposomes
were incubated for 1 min at room temperature with 100 µl of 12 nM human α-thrombin
(Haematologic Technologies, Essex Junction, VT). The thrombin/liposome mixture was then
added to 500 µl of 100 µM Chromozym TH in Tris buffer. Thrombin activity against the
Chromozym TH substrate was assessed by measuring optical absorbance at 405 nm, indicative of
liberation of the 4-nitranaline group of Chromozym TH. To quantify the activity of uninhibited
thrombin, the change in absorbance per minute was recorded. The kinetics of PPACK-thrombin
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inhibition was fit to a model of thrombin inhibition by hirudin to estimate an apparent inhibition
constant K !' .21 Assuming binding to the enzyme causes a significant decrease in inhibitor
concentration, the variation of the steady-state velocity can be described in terms of K !' :
v!
v! =
2E!

K !' + I! -‐E!

!

!
!

+ 4K !' E! -‐ K !' + I! -‐E!

where the steady state velocity, v! , is shown as a function of v! , the velocity in the absence of an
inhibitor; I! , the total inhibitor concentration; E! , the total enzyme concentration; and K !' , the rate
constant where the substrate and the inhibitor compete for binding to the active site, as is the case
with PPACK inhibition of thrombin.
To test PPACK-Liposome activity against clot-bound thrombin, clots were made by
combining 2.25 µl of 1U/µl bovine thrombin (Sigma-Aldrich, St. Louis, MO), 16.5 µl of 500
mM CaCl2 and 281.5 µl of human plasma, using the cap of a 1.5 ml eppendorf tube as a
template. The clots were then transferred to strips of nitrocellulose and aged in saline at 37˚C for
2 hours on an orbital shaker. After incubation, 50 µl of either saline, 12.5 mg/ml free PPACK,
precursor liposomes or PPACK-Liposomes were added and allowed to incubate with the clots
for 1 hour. After liposome incubation, the clots were rinsed with saline and weighed. The clots
were then submerged in a mixture of 3.77 ml of human plasma and 220 µl of 500 mM CaCl2 and
allowed to incubate for intervals of 5, 15, 30, 60 and 180 minutes. At the conclusion of each time
point, the clots were rinsed in saline and weighed.
For the visual determination of PPACK-liposome binding to clot-bound thrombin, the
previously described protocol was slightly altered. Clots were made as previously described,
combining thrombin, CaCl2 and human plasma in a template. The clots were aged in saline for 2
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hours at 37˚C on a shaker, followed by the addition of either non-targeted or PPACKfunctionalized fluorescent liposomes. The fluorescent liposomes were allowed to incubate for 1
hour at 37˚C. After incubation, the clots were rinsed in saline and transferred to 6-well plates
with fresh saline for imaging. Competition experiments were accomplished with the addition of
50 µl of 12.5 mg/ml PPACK followed by 2 hours of incubation and a subsequent saline rinse
prior to the addition of fluorescent PPACK-Liposomes. Clots were imaged using a Xenogen in
vivo imaging system (IVIS) Spectrum Workstation (Caliper Life Sciences, Hopkinton, MA) at
excitation and emission wavelengths of 535 and 580 nm, respectively. Radiant efficiency was
also measured for the imaged clots to gather a quantitative assessment of PPACK-Liposome
binding. Additionally, untreated clots were fixed and embedded in paraffin for histological
analysis of fibrin content.
Platelet aggregometry was carried out to assess the inhibition of thrombin-mediated
platelet activation by PPACK-Liposomes. Blood collection protocols were approved by the
Washington University Institutional Review Board. Human donor whole blood was collected via
venipuncture into a syringe containing 3.2% sodium citrate for anticoagulation (1:10 citrate to
blood ratio). Platelet-rich plasma (PRP) obtained by centrifuging the anticoagulated whole blood
at 180g for 10 minutes at room temperature. The supernatant was carefully collected and the
remaining material was further centrifuged at 1200g for 20 minutes at room temperature to
obtain platelet-poor plasma (PPP).22,23 PPP was used as the standard for 100% light transmission.
Platelet aggregometry was conducted on a Model 300 Payton Aggregation System (Payton
Scientific, Inc., Buffalo, NY) at 37˚C. Briefly, 500 µl of PRP was mixed with 5 µl of either
water, 150 µM PPACK, precursor liposomes, or PPACK-Liposomes and stirred at 1000 RPM in
the aggregometer. The mixture was allowed to sit to ensure a stable baseline reading and upon
43

stabilization, 5 µl of 500 µM thrombin (5 µM final concentration) was added to the PRP mixture
and allowed to aggregate fully.
2.2.5 In vivo Inhibition of Thrombin Activity
The antithrombotic efficacy of PPACK-Liposome was defined according to their ability
to delay the onset of thrombosis in C57BL/6 mice that were subjected to photochemical injury of
the carotid artery. The mice were sedated with ketamine (87mg/kg)/xylazine(13mg/kg), followed
by isolation of the carotid artery through a midline cervical incision. To follow the kinetics of
occlusion after injury initiation, an ultrasonic Doppler probe (Transonic Systems Inc, Ithaca,
NY) was placed on the carotid artery to measure the blood flow rate. Saline, free PPACK at 12.5
mg/ml, precursor liposomes (without surface modifications) or PPACK-Liposomes were
delivered via tail vein injection as a 1ml/kg bolus 10 minutes before the injection of
photosensitive Rose Bengal dye in phosphate-buffered saline to induce arterial injury upon
exposure to laser light. A 1.5 mW 540 HeNe laser was focused on the isolated carotid artery. The
experiment was terminated upon observation of the flow rate decreasing to < 15% of the original
flow and maintaining that level for >5 minutes. The injured carotids were removed and preserved
in paraffin for histological analysis of clot composition using the Carstairs stain for fibrin and
platelets.24
For observation of liposome localization to the injury site, fluorescent PPACKLiposomes were administered and the right carotid artery was exposed to photochemical injury
for 30 minutes. The mice were euthanized and the injured carotid arteries were excised and
embedded in Optimal Cutting Temperature (OCT) medium and sectioned for fluorescence
microscopy.
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2.2.6 Activated Partial Thromboplastin Time
To measure the effects of PPACK-Liposome treatment on activated partial
thromboplastin time (APTT), a series of C57BL/6 mice were injected with a bolus of PPACK
Liposomes with terminal left ventricle blood draws at 10, 20, 50, and 100 minutes post-injection.
The mice were sedated with ketamine (87mg/kg)/xylazine(13mg/kg) and blood was drawn from
the left ventricle into a syringe with 4% sodium citrate for anticoagulation (1:10 citrate to blood
ratio). Blood samples were subsequently spun in a microcentrifuge for 15 minutes at 1000g.
After centrifugation, the plasma was aspirated and frozen for future use. APTT kits (HemosIL,
Lexington, MA) were used to obtain data for each time point. 100 µl of APTT reagent (colloidal
silica with a mixture of synthetic phospholipids, buffer and preservatives) was added to 100 µl of
thawed plasma and allowed to incubate for 3 minutes. 100 µl of 25 mM calcium chloride was
then added to the reagent-plasma mixture and APTT was determined through mechanical
agitation of the mixture.
2.2.7 Biodistribution
DiI-labeled PPACK-Liposomes were utilized to assess biodistribution and avenues of
liposome clearance after 2 hours of circulation. C57BL/6 mice were given either no injection to
serve as a control, or DiI-PPACK-Liposomes (1ml/kg) via tail-vein injection. Mice were
euthanized 2 hours post-injection and perfused with saline. The liver, spleen, and kidneys were
removed and imaged in a Xenogen IVIS Imaging Workstation as previously described for
imaging DiI-labeled liposomes. Total radiant efficiency was measured to give a quantitative
measurement of liposome accumulation in the organs.

45

2.2.8 Statistics
In vivo thrombin inhibition and in vitro clot growth data was analyzed using the KruskalWallis ranked sum test, where P < 0.05 demonstrates statistical significance. For all other data, a
two-sided Wilcoxon ranked sum test was used, where P < 0.05 demonstrates statistical
significance. Error bars represent standard error of the mean.
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2.3 Results
2.3.1 PPACK-Liposome Synthesis and Characterization
After sonication-extrusion treatment of lipid films, liposomes were synthesized with
exposed terminal carboxy-PEG ends by incorporation of DSPE-PEG-COOH. The carboxyterminated ends were activated with EDCI to form amide bonds with the N-terminus of PPACK.
(Fig. 2-1A) The resulting PPACK-Liposome complex, along with the bare liposomes were
analyzed with dynamic light scattering to determine the particle size of the resulting
formulations. The bare precursor carboxy-terminated liposomes exhibited a mean hydrodynamic
diameter of 163.2 ± 3.89 nm, while the PPACK-liposomes exhibited a mean hydrodynamic
diameter of 170.78 ± 10.589 nm. (Fig. 2-1B) TEM images were also obtained to observe
liposome morphology. (Fig. 2-2) Zeta potential was used to further characterize the stability of
the liposome formulations. The precursor liposomes exhibited a zeta potential of -31.92 ± 11.43
mV, while the PPACK-terminated liposomes exhibited a zeta potential of -13.45 ± 2.00 mV.
(Fig. 2-1B) Because of the positively charged amino acid in the PPACK peptide, this difference
in zeta potential confirms successful conjugation of PPACK to the surface of the liposome. In
addition, RP-HPLC quantification (Fig. 2-3A) of liposomal PPACK concentration, combined
with Stewart assay quantification (Fig. 2-3B) of liposome concentration indicated the coupling of
6254.24 ± 1245.14 PPACK peptides per liposome.
2.3.2 In Vitro Inhibition of Thrombin
The chromogenic substrate Chromozym TH was utilized to measure thrombin activity in
vitro. Varying amounts of free PPACK or PPACK-Liposomes were added to a solution of
thrombin in order to demonstrate a dose-dependent inhibition of thrombin. After a one-minute
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incubation time, the thrombin/inhibitor mixtures were added to a solution of Chromozym TH in
Tris buffer and the cleavage of Chromozym TH was allowed to occur. The results of the
Chromozym TH assay were further used to estimate the apparent K !' for PPACK inhibition of
thrombin. The Chromozym TH data was fit to a standard model of tight-binding inhibition of
thrombin by hirudin, as previously described.21 The results showed a K !' of liposome-conjugated
PPACK was 172.6 nM, and that of free PPACK was 12.07 nM. (Fig. 2-4)
Next, an in vitro assay was developed to study the ability of PPACK-Liposomes to
inhibit clot-bound thrombin and prevent further growth of clots after plasma incubation. (Fig 25A) Standardized clots were produced in vitro by incubating thrombin, plasma and CaCl2
together in a template for one minute. These clots were then removed from the template and
affixed to nitrocellulose paper, followed by exposure to buffer for 2 hours (Fig. 2-5B. Then, clots
(3-6 clots per group) were exposed to either 5 ml of buffer or 12.5 mg/ml free PPACK, Precursor
Liposomes, or PPACK-Liposomes in buffer (50 µl in 5 ml of PBS) for 60 minutes, washed three
times, and then incubated in plasma for selected intervals to observe clot growth according to
clot weight (Fig. 2-5A, C-F). After 15 minutes of incubation in plasma, the weight of the saline
control (Fig. 2-5C) and precursor liposomes (Fig. 2-5E) clots grew to greater than 500% of the
initial weight of the pre-incubation clot, totally filling the well of a 6-well plate with new clot. A
similar, but more gradual increase in clot size was observed for clots treated with free PPACK,
finally reaching a size approximately 800% of the initial clot weight at the end of the 180-minute
plasma exposure time (Fig. 2-5D). This significant increase was observed for all subsequent time
points and was potentially limited by the restrictions of the size of the well in the plate. Clots
treated with PPACK-Liposomes did not grow significantly over 180 minutes (Fig. 2-5F).
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Accordingly, PPACK-Liposomes completely prevented new clot growth, or “regrowth,” as
compared to the control treatments.
To confirm the localization of the PPACK-Liposomes to the clots, liposomes were
synthesized with the incorporation of the carbocyanine dye, DiI. Clots (N=6 per group) were
grown and incubated with non-targeted liposomes, PPACK-functionalized liposomes, or no
treatment. In addition, one group of clots was treated with 12.5 mg/ml free PPACK to block
thrombin in the clot, followed by treatment with PPACK-Liposomes to observe any nonspecific
interactions of PPACK-Liposomes with the clots. The clots were then imaged with an IVIS
Spectrum Workstation after washing away excess, non-bound particles. PPACK-Liposomes
exhibited significantly higher amounts of bound particles compared to the control liposomes and
the competition group (Fig. 2-6A), as confirmed by a quantitative measurement of total radiant
efficiency. (Fig. 2-6B)
PPACK-Liposomes also displayed the ability to effectively inhibit thrombin-mediated
activation of platelets through platelet aggregometry measurements. In the presence of water or
precursor liposomes, where PPACK is completely absent, platelets rapidly aggregated upon
addition of thrombin at a concentration of 5 µM in the cuvette. In the control group where free
PPACK is present in the PRP, platelets exhibited no aggregation throughout the duration of the
experiment. PPACK-Liposomes demonstrated a similar ability to ablate platelet aggregation.
(Fig. 2-7)
2.3.3 Inhibition of Thrombus Formation in vivo
To delineate the efficacy of the PPACK-Liposomes in vivo, injury of the carotid artery of
C57Bl/6 mice was induced by the traditional photochemical/laser method in mice each treated
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with either saline (N=6), free PPACK (N=4), Precursor Liposomes (N=4) or therapeutic
PPACK-liposomes (N=6). The efficacy of liposomes for inhibition of thrombosis was measured
by denoted time required to reach complete occlusion. Precursor liposomes with no PPACK
functionality served as the liposome control. When injected 10 minutes prior to induction of
arterial trauma, the control liposomes yielded an occlusion time of 85.75 ± 18.24 min. This
exhibited no significant increase over the saline-treated group of 69.06 ± 5.65 min or the free
PPACK group of 71.33 ± 9.46 min. In addition, the free PPACK group showed no significant
increase over the saline treated group. In the PPACK-Liposome treated mice, occlusion time was
prolonged to 139.75 ± 20.46 min and was significantly increased compared to all other groups.
(Fig. 2-8A) Additionally, the activity of PPACK-Liposomes appeared to exhibit a continuous
effect at the injury site as determined by flow rate monitoring throughout the course of the
injury. (Fig. 2-8B) Site-specificity and fluorescent PPACK-Liposome accumulation in the clot
was observed through fluorescence microscopy evaluation (Fig. 2-8C) of partially formed clots
(Fig. 2-8D) in excised carotid arteries. The results of this study indicate that the addition of
PPACK to the surface of the liposomes provides the needed functionality to serve as a thrombin
inhibitor in vivo.
Activated partial thromboplastin time (APTT) testing was carried out in mice treated with
PPACK-Liposomes. (Fig. 2-9) Liposome treatment resulted in an initial prolongation of APTT
up to 65.98 ± 19.59 seconds at 10 minutes after the administration of PPACK-Liposomes.
Prolonged APTT was observed 20 minutes after treatment, but followed by a return to the
control range within 50 minutes after treatment. The normalization of systemic APTT values did
not affect the prolonged therapeutic action at the site of injury since in vivo inhibition of
thrombus formation was observed beyond 2 hours in the carotid artery.
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2.4 Discussion
The tripeptide agent PPACK is recognized as a potent candidate for antithrombotic
applications due to its high affinity for thrombin and low systemic toxicity with an LD50 of >50
mg/kg. However, its fast clearance rate (T1/2 ~ 3 minutes) in vivo precludes clinical application.16
To overcome the rapid systemic clearance, we conjugated PPACK to the surface of a liposome,
which yields an agent that manifests prolonged anti-thrombin activity at the site of an acute
clotting event, yet its systemic anticoagulant activity rapidly wanes after injection. The
anticoagulant nanostructure design has the advantage of exposing multiple anticoagulant sites on
the surface of the liposome to achieve exceptional thrombin avidity and markedly enhanced local
anticoagulation efficacy. Moreover, the aqueous compartment of the liposome offers the
potential of encapsulating drugs for possible localized combination anticoagulation or
thrombolytic therapy.
PPACK-Liposomes are capable of binding to and inhibiting clot-bound thrombin as
shown by the in vitro clot growth assays and fluorescent imaging (Fig. 2-6). Remarkably,
PPACK-Liposomes completely prevented further clot growth in this system, which offers a
distinct advantage over heparin that is unable to associate with clot-bound thrombin due to
masking of the heparin-binding site on fibrin-bound thrombin.25,26 The establishment of a highly
focal, long-lasting multivalent anticlotting surface atop a newly forming clot appears to sequester
procoagulant materials from serum clotting factors that otherwise might continue to promote
coagulation through activation of Factor VIII or other factors.27
In vivo experiments of carotid occlusion time post-injury confirmed the efficacy of the
PPACK-Liposomes, demonstrating an ability to prolong the formation rate of occlusive arterial
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thrombi after the administration of one pre-injury bolus treatment. The use of multiple dosing
regimens and treatment of pre-formed thrombi in vivo will be the subject of future investigation
to advance towards clinical translation and establish a maximum effective dose.
The prolonged occlusion times in the Rose Bengal mouse model are a consequence not
only of the inhibition of thrombin at the site of injury, but also reduced platelet activation and
aggregation that depends on thrombin interacting with various platelet receptors28, including
GPIbα29,30, PAR-1 in humans31, and PAR-4 in the mouse.32-34 This activation of platelets by
thrombin is completely inhibited in the presence of PPACK-Liposomes as confirmed by platelet
aggregometry. (Fig. 2-7) This dual functionality likely amplifies the potency of the agent at the
site of acute clotting without disrupting alternative mechanisms of platelet activation that would
be useful to maintain hemostasis elsewhere. Moreover, despite the prolonged activity of PPACKLiposomes at the site of injury, the systemic action of PPACK-Liposomes rapidly declines
between 20-50 minutes after injection according to activated partial thromboplastin times. This
rapid diminution of systemic anticoagulant effect is due to the removal of a sufficient amount of
circulating thrombin-targeted liposomes by the liver and spleen (Fig. 2-10) to drop blood pool
levels below that required to inhibit further clotting while still providing an enormous focal pool
of PPACK at the site of thrombosis to immediately inactivate any subsequently released
thrombin.
The limitations of PPACK as an antithrombotic agent also comprise its broader
specificity as a protease inhibitor beyond thrombin, although the rapid clearance of the unbound
liposomes mitigates this concern. This point might also apply equally to the concern of the
irreversible nature of the interaction with the active site on the thrombin molecule. Nevertheless,
it is probable that alternative anticoagulant molecules such as bivalirudin could serve a similar
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purpose when conjugated to a liposome to enhance specificity in a reversible interaction if
required. A pluripotent design with multiple specific factor inhibitors could promote synergism
for the formed anticlotting surface without having to completely attenuate any one factor alone.
The use of a liposomal structure may occlude the interaction of some of the PPACK due
to potential steric and mobility effects of liposome-bound PPACK, limiting the freedom of
PPACK to invade the active site of thrombin. This possibility may explain the increased K !' of
the PPACK conjugated liposome versus free PPACK noted in the model-based analyses of
affinity, as not all of the included PPACK would be active against thrombin as long as the
liposome remained intact. However, due to the high avidity achieved by including copies of
PPACK, high local activity should be maintained as shown by the in vivo clot inhibiting
experiments.
Previous reports have suggested the potential of nanometer-sized particles to act as
effective anticoagulants in vivo, in some cases involving surface modifications to promote
anticoagulant activity.8,9,11 However, the use of liposomes as anticoagulant structures has the
advantage that they are established as a vehicle for biomedical applications with an abundance of
FDA-approved liposomal formulations. Furthermore, the opportunity to encapsulate drugs or
imaging agents ultimately could facilitate detection and localized treatment of acute thrombi in
emergency situations. This benefit is vital—especially when triage to medical versus surgical
therapy might necessitate ensuring normalized systemic clotting parameters at the time of
decision, which is possible with this agent without the need for an “antidote”.
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Figure 2-1

Figure 2-1: (A) Schematic of EDCI-mediated PPACK conjugation to carboxyl-terminated
liposomes. (B) Size and zeta potential of carboxyl-terminated liposomes and PPACKLiposomes. Results indicate a hydrodynamic diameter of 163.2 ± 3.89 nm and zeta potential of 31.92 ± 11.43 mV for the carboxyl-terminated liposomes. PPACK liposomes exhibit a diameter
of 170.78 ± 10.59 nm and zeta potential of -13.45 ± 2 mV. The rise in zeta potential is indicative
of the increased positive surface charge on the liposomes after PPACK conjugation.
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Figure 2-2

A

B

Figure 2-2: (A) TEM Image of precursor carboxyl-terminated liposomes. Scale bar denotes 100
nm. (B) TEM Image of PPACK-Liposomes. Scale bar denotes 100 nm. Both samples were
negatively stained with the vanadium-based stain NanoVan.
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Figure 2-3

Figure 2-3: (A) Standard curve of PPACK quantified by RP-HPLC. The standard curve was used
to determine the amount of uncoupled PPACK left over after the conjugation step. (B) Stewart
Assay standard curve to quantify the amount of phospholipids in the liposome sample. The
Stewart Assay quantification was then used to determine the liposome concentration given the
overall size of the liposome measured by dynamic light scattering. Both assays were then used in
tandem to determine the number of PPACK molecules per liposome (6254.24 ± 1245.14 PPACK
peptides per liposome).
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Figure 2-4

Figure 2-4: Demonstration of inhibition of thrombin activity against the chromogenic substrate
Chromozym TH. PPACK-Liposomes exhibited an inhibition constant of 172.6 nM compared to
an inhibition constant of 12.077 nM for free PPACK.
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Figure 2-5

Figure 2-5. In vitro clot assay demonstrating the inhibition of clot-bound thrombin by PPACKLiposomes. (A) Measurement of clot growth after incubating saline, free PPACK, Precursor
liposomes or PPACK-Liposome-treated clots in plasma for selected time points. Clots treated
with saline, free PPACK and Precursor Liposomes all exhibited significant growth after 3 hours
of plasma incubation compared to PPACK-Liposome treated clots. (*P < 0.05) (B-F)
Representative images of clots before (B) and after (C-F) plasma incubation, comparing clots
from all treatment groups after 3 hours of plasma incubation.
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Figure 2-6

Figure 2-6: (A) Fluorescent images of clots treated with either saline, DiI-labeled carboxylterminated liposomes (Non-Targeted) or DiI-labeled PPACK-Liposomes (Targeted).
Competition experiments refer to prior inhibition of clot-bound thrombin with free PPACK
followed by treatment with DiI-labeled PPACK-Liposomes. (B) Measurement of Total Radiant
Efficiency demonstrating that liposome binding to clot was significantly increased with PPACK
functionalization. (**P<0.005, N = 6 for non-targeted, PPACK liposomes, and competition
groups) Additionally, competition experiments demonstrated specificity through low association
of PPACK-Liposomes with clots previously treated with free PPACK.
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Figure 2-7

Figure 2-7: The effect of PPACK-Liposomes on thrombin-mediated aggregation of human
platelets was evaluated using platelet aggregometry, where 100% light transmittance represents
100% aggregation. Platelet-rich plasma (PRP) containing either (A) water, (B) Precursor
Liposomes, (C) free PPACK, (D) PPACK-Liposomes was exposed to thrombin and allowed to
aggregate. The red arrow indicates the addition of thrombin to the PRP. The presence of PPACK
or PPACK-Liposomes in the PRP abolishes thrombin-mediated activation of platelets.
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Figure 2-8

Figure 2-8: (A) Time to occlusion of carotid artery with the Rose Bengal dye injury model in
mice treated with Saline, free PPACK, Precursor Liposomes or PPACK-liposomes. Occlusion
time was significantly increased for the PPACK-Liposome group over all other groups
(**P<0.005) demonstrating potent antithrombotic activity in vivo. (B) Representative
measurements of flow rate through the injured carotid artery throughout the duration of the in
vivo photochemically-induced thrombus formation model. The formation of the thrombus
continues over the entire course of the experiment—a process that is gradually delayed with
PPACK-Liposome treatment. The time course for thrombus formation was largely unchanged for
saline, Free PPACK and Precursor Liposomes. (C) Localization of PPACK-Liposomes (white
arrows) at site of initial clot formation. (D) H&E stain of neighboring section showing initial
formation of clot and endothelial damage. Scale bars represent 100 µm.
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Figure 2-9

Figure 2-9: Activated partial thromboplastin time for PPACK-Liposome treated mice
demonstrating a significant increase in APTT (*P<0.05) compared to the normal range 10 and 20
minutes after PPACK-Liposome injection, followed by a return to the control range within 50
minutes after injection.
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Figure 2-10

Figure 2-10: Biodistribution of PPACK-Liposomes after 2 hours of circulation time. The light
grey bars represent baseline organ fluorescence from mice that received no injections. The
clearance of PPACK-Liposomes from the circulation appears to be mediated by the liver and
spleen.
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Chapter 3: Inhibition of Stent Thrombosis using ThrombinInhibiting Perfluorocarbon Nanoparticles
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Chapter Overview
Despite significant advances in intravascular stent technology, safe prevention of stent
thrombosis over prolonged periods after initial deployment persists as a medical need to reduce
device failure. The objective of this project was to assess the potential of perfluorocarbon
nanoparticles conjugated with the direct thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl
chloromethylketone (PPACK-NP) to inhibit stent thrombosis.
In a static model of stent thrombosis, 3 mm x 3 mm pieces of stainless steel coronary
stents were cut and adsorbed with thrombin to create a procoagulant surface that would facilitate
thrombus development. Following treatment with PPACK-NP or control NP, stents were
exposed to platelet poor plasma (PPP) or platelet rich plasma (PRP) for set time points up to 60
minutes. Measurements of final clot weight in grams were utilized for assessing the effect of
nanoparticle treatment on limiting thrombosis. Additionally, groups of stents were exposed to
flowing plasma containing various treatments (saline, free PPACK, control NP and PPACK-NP)
and generated thrombi were stained and imaged to investigate the treatment effects of PPACKNP under flow conditions.
The static model of stent thrombosis utilized in this study indicated a significant
reduction in thrombus deposition with PPACK-NP treatment (0.00067 ± 0.00026g, N=3)
compared to control NP (0.0098 ± 0.0015g, N=3, p = 0.026) in PPP. Exposure to PRP
demonstrated similar effects with PPACK-NP treatment (0.00033 ± 0.00012g, N=3) versus
control NP treatment (0.0045 ± 0.00012g, N=3, p = 0.000017). In additional studies, stents were
exposed to both platelet rich plasma pretreated with vorapaxar and PPACK-NP, which illustrated
adjunctive benefit to oral platelet inhibitors for prevention of stent thrombosis. Additionally, an
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in vitro model of stent thrombosis under flow conditions established that PPACK-NP treatment
significantly inhibited thrombus deposition on stents.
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3.1 Introduction
Stroke, myocardial infarction, and limb loss from peripheral vascular disease are
significant causes of cardiovascular morbidity and mortality in the U.S. that often are treated
with interventions requiring one or more stents.1 Over the past few decades, significant
technological advances have been made in these interventional treatments, yet all such therapies
continue to fail a significant portion of patients due to thrombosis as the final common endpoint.
In fact, recent reports from the Dual Antiplatelet Therapy (DAPT) study have demonstrated that
the current standard of dual antiplatelet therapy (P2Y12-receptor inhibitor plus aspirin) for
prevention of thrombotic complications following placement of drug-eluting stents may require
extended use beyond 1 year following stenting to prevent thrombosis, instead of the commonly
prescribed 6-12 months.2
Despite this demonstration of a reduction of risk of stent thrombosis and major adverse
cardiovascular and cerebrovascular events with therapy for >1 year, the prolonged treatment
regimen harbors an increased risk of bleeding, suggesting a clear medical need for new
antithrombotic and antiplatelet agents that provide increased efficacy in preventing thrombotic
complications, while minimizing bleeding risk. These studies also highlight the clinically
significant rate of stent thrombosis for intravascular stents in the carotid, coronary and peripheral
circulation. Intravascular stents continue to experience thrombosis at rates in coronary circulation
of 0.9% at 30 days post-implantation with second-generation drug eluting stents3, but highly
variable rates in the peripheral circulation with failure rates up to 25%.4,5 Significantly, the
immediate incidence of death or myocardial infarction is 64.4% for coronary stent thrombosis3
and in the peripheral circulation stent thrombosis can result in limb loss, stroke, renal failure or
bowel ischemia. Aggressive and prolonged pharmacological therapy with platelet inhibitors is
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required to mitigate the prothrombotic tendency of stents until they become endothelialized and
more resistant to thrombosis, but at the cost of significant and sustained bleeding risk. Indeed
the published data indicate a severe bleeding risk of 1.7% and moderate bleeding risk of 2.1%
over 28 months with the highest risk during the first year and significant additional mortality
with moderate bleeding events.6 We propose an alternative solution to maintaining stent patency
while minimizing bleeding risk by exerting a localized anticlotting effect devoid of any sustained
systemic anticoagulant effect. To address this clinical need, this study assessed the ability of antithrombin PFC NPs to prevent thrombosis on thrombin treated stents in both static and flow invitro models.
The agents utilized in this study consist of perfluorocarbon nanoparticles (PFC-NP) with
a diameter of 160.5 ± 2.6 nm that were conjugated to the direct thrombin inhibitor PPACK (Dphenylalanyl-L-prolyl-L-arginyl chloromethylketone) to form antithrombotic nanoparticles,
PPACK-NP (Fig. 3-1A).7 These nanoparticles were formulated to carry ~13650 PPACK
moieties per particle, and already have demonstrated favorable safety profiles in vivo with
respect to bleeding risk, with APTT and mouse tail vein bleeding times normalized within 60
minutes following intravenous administration. Furthermore, PPACK-NP are effective
antithrombotic agents in mouse models of arterial thrombosis, where prior work has
demonstrated that PPACK-NP treatment more than doubles the time to total thrombotic
occlusion of the carotid artery after dye-laser injury by directly inhibiting thrombin activity at the
site of injury. Additionally, as thrombin accumulated, PPACK-NP continually bound and
inactivated all exposed thrombin molecules ultimately forming an "anti-clotting" surface (Fig. 31B).8 The anti-thrombin activity of the nanoparticle PPACK system in vivo is greatly improved
over that of free PPACK due to an increased circulating half-life (t1/2 ~ 3 min for free inhibitor9
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vs. t1/2 ~ 105 min for PPACK-NP as a direct consequence of conjugation of the active PPACK
moiety to the stable nanoparticle.10 Even though PPACK is a potent direct and irreversible
inhibitor of thrombin by covalently coupling to the active site of the protease, its lack of
acceptable pharmacokinetics render it essentially useless as a clinical anticoagulant unless
coupled to a nanosystem to extend its clearance time.
Herein, we sought to define the utility of PPACK-NP for inhibiting stent thrombosis in
both static and dynamic models of thrombosis in vitro. PPACK-NP were assayed under
conditions of stent exposure to platelet poor (PPP) and platelet rich plasma (PRP), and also tested
in conjunction with Vorapaxar treatment to delineate an additive antithrombotic effect of
PPACK-NP, which we hypothesize will occur through decreased thrombin mediated protease
activated receptor-1 (PAR-1) platelet activation with PPACK-NP and through Voraxapar as it
directly blocks PAR-1 along with diminished activity of thrombin in cleaving fibrinogen as a
consequence of PPACK-NP therapy, in the prevention of stent thrombosis. Dynamic models of
stent thrombosis were utilized to generate thrombi on stents under flow conditions, and PPACKNP were tested for their ability to prevent the formation of an occlusive thrombus following
infusion of thrombin within a flow loop. The goal was to elucidate the beneficial effects of
PPACK-NP in the prevention of stent thrombosis that might support further development of both
novel nanoparticle coatings for stents and subsequent intravenous treatment regimens to prevent
or ameliorate thrombosis of stents or other intravascular prosthetics.
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3.2 Materials and Methods
3.2.1 Nanoparticle Formulation
Nanoparticles were synthesized according to previously established emulsification
techniques.7,8 Briefly, the precursor PFC-NP were composed of a 20% (vol/vol) perfluoro-15crown-5-ether (CE) core, 2% (wt/vol) surfactant, 1.7% (wt/vol) glycerin, and water. The
surfactant used in the formulation consisted of 99% egg phosphatidylcholine, EPC (Avanti Polar
Lipids, Alabaster, AL) and 1 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[carboxy(polyethylene glycol)-2000], DSPE-PEG2000-COOH (Avanti Polar Lipids, Alabaster,
AL). Following emulsification of the surfactant, CE, glycerin and water, the resulting precursor
PFC NP was activated for coupling to the free carboxyl groups using 2 mg/mL 1-ethyl-3-(3dimethylaminopropyl carbodiimide HCl, EDC (Pierce, Rockford, IL). Amine coupling of
PPACK to the nanoparticle surface was accomplished with the subsequent addition of 12.5
mg/ml PPACK (American Peptide Company, Sunnyvale, CA) to the activated precursor
nanoparticle and the conjugation reaction was allowed to proceed overnight. Following
conjugation, the excess EDC and uncoupled PPACK was removed from the nanoparticle
suspension using dialysis tubing of MWCO 3000-5000 (Spectrum Laboratories, Rancho
Dominguez, CA) and allowed to filter for 4 hours.
3.2.2 Static Model of Stent Thrombosis
For the static in vitro model of stent thrombosis, expired Guidant® bare metal stents
constructed of 316L stainless steel, were acquired from the Washington University in Saint
Louis’ Department of Medicine. Stents were expanded and cut into 3 x 3 mm sections and placed
into wells of a 12-well plate. To model potential biofouling and accumulation of prothrombotic
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material on stents following deployment, the stent sections were incubated with 10 µl of 1 U/µl
bovine thrombin (Sigma-Aldrich, St. Louis, MO) for 1 hour. Following incubation, the stents
were rinsed with saline to remove any unadsorbed thrombin. To confirm the presence of
thrombin on the stent surface, the activity of adsorbed thrombin on the stent surface was tested
against a chromogenic substrate for thrombin, S-2238 (Diapharma, West Chester, OH). Stents
with or without adsorbed thrombin were incubated with 100 µl of 333 µM S-2238 for 30
minutes, after which the reacted S-2238 solution was transferred to wells of a 96-well plate and
absorbance was measured at 405 nm.
To test the efficacy of PPACK-NP treatment in this static model, thrombin-adsorbed stent
sections were treated with 10 µl of either saline, free PPACK (12.5 mg/ml), control NP, or
PPACK-NP and allowed to incubate for 1 hour. In this and subsequent experiments, the control
NP used were the precursor PFC NP prior to amine coupling of PPACK. Following treatment,
the stents were then washed with saline to remove any non-stent associated nanoparticles. The
treated stents were then exposed to, platelet poor plasma (PPP), generated through the addition of
500 mM CaCl2 to aliquots of expired human plasma. In the investigation of the effect of dual
treatment with platelet inhibitors, platelet rich plasma (PRP) was made through the dilution of
expired human platelet concentrate (ZenBio, Research Triangle Park, NC) in PPP, resulting in a
total platelet concentration of 300,000 platelets/ml. For test groups including platelet inhibitors,
PRP was pretreated with Vorapaxar (Axon Medchem LLC, Reston, VA) at a final concentration
of 50 nM. The treated stents were incubated with 10 µl of PPP, PRP or PRP/Vorapaxar for
designated time points of 5, 15, 30, and 60 minutes at 37˚C, N=3 for each group at each time
point. At each of these time points, stents were weighed to determine clot weight following
plasma incubation.
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3.2.3 Ultrasound Imaging of Thrombosed Stent Sections
Samples were placed in room temperature saline at the focal zone of a high-frequency
ultrasound scanner (Vevo 660 with RMV-704 40-MHz probe, VisualSonics, Toronto, ON,
Canada). The probe was mounted to a computer-controlled gantry to permit scanning in multiple
image planes, where each plane corresponded spatially to a cross-sectional view that was 8.0 mm
wide and 1.9 mm deep. Raw radio-frequency (RF) data were acquired and stored as the probe
was scanned over the sample surface. The backscattered energy at each point in the digitized
waveforms making up an image frame was computed from the log of the sum of the squared RF
amplitudes in a center-weighted moving window. These values were mapped to grayscale and
scaled to the appropriate physical dimensions to form cross-sectional images of the sample, with
acoustically 'bright' areas represented in white and non-echogenic regions in black.
3.2.4 Scanning Electron Microscopy
Stent sections harboring thrombi were prepared for scanning electron microscopy to
visualize the presence of deposited fibrin and platelets on the stent surface. Following clot
growth, stent sections were each placed into wells of a 12-well plate containing 1 ml of freshly
prepared 2% gluteraldehyde (Sigma-Aldrich, St. Louis, MO) overnight at 4˚C for fixation. After
fixation, the stent sections were serially dehydrated in 1-hour incubations with 10%, 30%, 50%,
70%, 90% and 100% (3x) ethanol. Following dehydration, the stent sections were placed in a
vacuum dessicator overnight to remove any residual moisture. The stent sections were then
sputter coated with gold for 90 seconds followed by imaging with a Hitachi S-2600H and FEI
Nova Nano 2300. ImageJ v1.47 was utilized to determine the diameter of nanoparticles
visualized on stents.
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3.2.5 In Vitro Flow Model of Stent Thrombosis
To test the ability of PPACK-NP to prevent stent thrombosis under flow conditions, a
flow loop was utilized to simulate thrombus formation under flow conditions. The stent was
deployed in Tygon tubing and 15 ml of PRP (150,000 platelets/ml) containing 50 µl of either
saline, free PPACK (12.5 mg/ml), control NP, or PPACK-NP was allowed to flow in a loop
using a peristaltic pump at 50 ml/min. After continuous perfusion of the flow loop with plasma,
10 µl of 1 U/µl bovine thrombin was infused into the flow loop and the plasma was allowed to
flow for 10 mins. After 10 minutes, stents were removed from the flow loop, fixed overnight in
10% formalin and stained with picrosirius red for 30 minutes to obtain images of thrombus
deposition on the stent.
3.2.6 Effect of PPACK-NP on aortic endothelial cell proliferation
Human aortic endothelial cells (HAECs) were acquired from Lifeline Cell Technology
(Frederick MD). HAECs were cultured in VascuLife EnGS Complete Medium (Lifeline Cell
Technology) prior to detachment with 0.05% trypsin-EDTA and plating in a 96 well plate at
10,000 cells/well. Following overnight cell attachment, the growth medium was replaced with
EnGS complete medium with 1% penicillin-streptomycin-amphotericin (PSA, LS-1085, Lifeline
Cell Technology) containing 1 U/ml human thrombin (Haematologic Technologies, Essex
Junction, VT) plus equimolar amounts of free PPACK, precursor NP and PPACK-NP. The cells
were allowed to incubate for 4 days with gentle shaking to prevent precipitation of nanoparticles.
Following 4 days of incubation, proliferation of HAECs was determined using an XTT assay
(Biotium Inc., Hayward, CA) as per the manufacturers instructions.
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3.2.7 Statistics
All statistical tests were performed on R, version 3.0.1. For the static model of stent
thrombosis, the Student’s t-test was utilized, where p < 0.05 denotes statistical significance. All
error bars are depicted as standard error of the mean.
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3.3 Results
3.3.1 Evaluation of PPACK-NP in a static model of stent thrombosis
We initially seeded sections of stents with thrombin to facilitate the further accumulation of
procoagulant material on the stent surface. Thrombin adsorption to the stent surface was
quantified through incubation of thrombin treated stents with S-2238, a chromogenic substrate
that liberates a p-nitroanilide group following specific cleavage by thrombin, thus producing an
absorbance peak at 405 nm. Thrombin-treated stents significantly increased the amount of S2238 cleavage when compared to saline controls (p = 0.00000052, n = 3 per group), confirming
the presence of thrombin on stent surfaces (Fig. 3-2A).
The efficacy of PPACK-NP was assayed in comparison to saline, free PPACK and plain
NP controls. Initial work was performed with platelet poor plasma (PPP) to isolate the effect of
PPACK-NP for inhibiting the formation of primarily fibrin clots (Fig. 3-2B). In the absence of
thrombin inhibiting compounds (PPACK or PPACK-NP), we observed that treatment with saline
and control NP resulted in a gradual time-dependent increase in clot weight. Treatment of
thrombin-adsorbed stents with PPACK or PPACK-NP results in minimal fibrin clot formation,
which was indicative of passivation of the procoagulant stent surface.
As thrombin exerts pleiotropic thrombotic and signaling effects, we aimed to explore the
role of PPACK-NP for inhibiting platelet activation on stents. Platelet-rich plasma (PRP) was
generated through supplementation of platelet concentrate into samples of PPP, with a final
concentration of 300,000 platelets/ml used in each experiment. Additionally, separate groups of
stents were exposed to Vorapaxar treated plasma to delineate the benefit of PPACK-NP in
conjunction with an established platelet inhibitor. PRP exposure to stents (Fig. 3-2C) resulted in
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rapid clot formation within 5 minutes of exposure and plateaued for the duration of the
experiment in saline and control NP treated groups. PPACK and PPACK-NP treatments resulted
in little to no clot deposition on stents following 60 minutes of PRP exposure. This lack of clot
deposition on stents was also observed in stents treated with PPACK and PPACK-NP after
exposure to platelet-inhibitor treated plasma. In the case of Vorapaxar-treated plasma, PPACK
and PPACK-NP inhibited stent thrombosis with greater efficacy than did Vorapaxar alone (Fig.
3-2D).
Ultrasound imaging of clots revealed a dense clot deposited on the surface of stents
treated with saline, compared to imperceptible clot deposition in stents treated with PPACK-NP
(Fig. 3-2E). The morphology of platelet-rich clots was observed by scanning electron
microscopy of stents following 60 minutes of PRP exposure for each stent treatment group. SEM
evaluation revealed a dense fibrin network formed on stent surfaces treated with saline (Fig. 33A) and control nanoparticles (Fig. 3-3B), with platelets embedded within fibrin clots in the
saline treated stents. PPACK treated stents (Fig. 3-3C) demonstrated only a very thin layer of
fibrous material deposited on the stent surface, consistent with clot weight measurements
confirming very little accumulation of clot on stent surfaces in the static model of stent
thrombosis. Interestingly, in PPACK-NP treated stents (Fig. 3-3D), the surface of the treated
stents showed the deposition of circular nanostructures and a lack of fibrin or platelets. We
hypothesized that the circular particles on the surface of the stent were particles that had adhered
to the stent surface, with their flat appearance on SEM due to the vacuum drying step in SEM
preparation that results in evaporation of the perfluorocarbon core and subsequent collapse of the
particle, leaving a flattened deposit of the collapsed PFC-NP lipid monolayer. The diameter of
these deposited particles was observed to be 185.46 ± 2.92 nm, as measured by ImageJ.
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3.3.2 Evaluation of PPACK-NP in an in vitro flow model
Following the evaluation of PPACK-NP in the static stent thrombosis model, we
investigated the ability of PPACK-NP to prevent clot formation in flowing, platelet rich plasma
(Fig. 3-4). In this model, a flow loop circuit was perfused with platelet-rich plasma at 150,000
platelets/ml together with selected nanoparticle or control solutions. Following complete
perfusion of the flow loop, 10 units of thrombin was infused and allowed to flow for 10 minutes,
after which the stents were removed and stained with picrosirius red to observe clot deposition.
The results of this experiment demonstrate the ability of PPACK-NP to prevent clot deposition
on prothrombotic materials such as a bare metal stent.
3.3.3 Effect of PPACK-NP on Endothelial Cell Viability and Proliferation
Because reendothelialization of denuded vascular regions and stent surfaces is crucial to
the wound healing response following stent implantation, we sought to define the effect of
PPACK-NP on endothelial proliferation. Proliferation was measured using an XTT assay (Fig. 35) that revealed a modest but significant decrease in proliferation after 4 days of continuous
exposure to thrombin (12.45% decrease, p = 0.011) or thrombin and control NP (11.24%, p=
0.049). PPACK and PPACK-NP treatment restored baseline endothelial proliferation levels
under these conditions suggesting an additional benefit of anti-thrombin nanoparticle in
accelerating local endothelial proliferation.
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3.4 Discussion
Previous experiments have attributed a potential mechanistic explanation for the efficacy
of antithrombin nanoparticles, where the presentation of multiple copies of thrombin inhibiting
peptides allows for the binding and retention of nanoparticles to clot-bound thrombin. This
retention of particles allows for the generation of an “anti-clotting” surface on top of a fresh
thrombus that delays or prevents future clot growth. This phenomenon represents an additional
benefit of antithrombin nanoparticle treatment, as treatment with free inhibitor only allows for
1:1 binding and would not establish such an antithrombotic surface.8,11 Furthermore, as each
particle can inactivate thousands of thrombin molecules, the continued surveillance and
inactivation of local thrombin results in a sustained thrombin “sponge” effect.
In static conditions, PPACK-NP treated stents exhibited markedly reduced clot burdens
than did saline or control nanoparticle both in platelet rich and platelet poor plasma. Ultrasound
imaging of stents along with scanning electron microscopy clearly revealed that PPACK and
PPACK-NP treated stents presented with essentially no clot deposition as compared to the dense
fibrin thrombi formed in control nanoparticle and saline control groups (Fig. 3-2B&C).
Furthermore, as antiplatelet therapy is a commonly prescribed as an adjunct to increase stent
patency, we investigated the effects of PPACK-NP on treated stents following exposure to
platelet inhibitor-treated PRP. As thrombin served as the agonist in these experiments, we tested
Vorapaxar (Zontivity, Merck), a recently FDA-approved direct protease-activated receptor-1
antagonist12 to block the activation of platelets by thrombin.13 Only a minor effect of Vorapaxar
was observed in preventing thrombus formation as compared to thrombus inhibition with
PPACK or PPACK-NP (Fig. 3-2D). This superiority of PPACK-NP treated stents over and
above Vorapaxar alone suggests that even in the event of diminished platelet activation due to
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vorapaxar treatment, the uninhibited effects of thrombin on fibrinogen cleavage still prevails in
formation of thrombi at injury sites. These results illustrate a strong potential adjunctive benefit
for the use of PPACK-NP either alone or in conjunction with other standard therapies.
We further explored this activity in an in vitro flow loop model to simulate a clinically
relevant scenario. Picrosirus red staining of stents following exposure to circulating PRP
demonstrated total occlusion of stents after saline and plain NP treatment, as compared to no
thrombosis in PPACK or PPACK-NP treated stents (Fig. 3-4). The present results suggest a
potential clinical utility for PPACK-NP as either stent coatings or through periodic intravenous
administration that would allow for effective antithrombotic activity with minimal bleeding side
effects, as previously demonstrated.7
Endothelialization of stents following implantation is a crucial step in healing of injury
sites14, and as such, we investigated the effect of PPACK-NP on endothelial proliferation (Fig. 35). Thrombin has previously been shown to promote wound healing through generation of
VEGF, and with inhibition of thrombin being potentially detrimental to endothelialization.
However, several groups have shown a concentration dependent and cell-type dependent effects
of thrombin on endothelial cell proliferation, where high concentrations of thrombin (>1U/ml)
have a detrimental effect on proliferation of aortic endothelial cells, as opposed to umbilical vein
endothelial cells. 15-17 Accordingly, we utilized human aortic endothelial cells for measurements
of proliferation in response to thrombin stimulation at 1U/ml for 4 days. A modest thrombindependent decrease in proliferation was observed for the control group, but basal cell
proliferation/viability was restored in the PPACK and PPACK-NP treated groups. These results
indicate that thrombin inhibition with PPACK-NP in this in vitro experiment preserved
endothelial proliferative potential on the face of high local concentrations of thrombin such as
83

those found in atherosclerotic plaques and vessel segments undergoing stenting.18 Additionally,
it is possible that treatment with PPACK-NP may have other related effects on the endothelium,
namely effects on cell migration and survival. Thrombin's role in vascular pathophysiology, for
example, includes the upregulation of NADPH oxidase secretion by vascular smooth muscles
cells19 that may contribute to reactive oxygen species (ROS)-mediated endothelial damage20 and
inhibition of endothelial cell migration.21 Thus along with the present data, and the effects of
thrombin on endothelial proliferation, migration and survival published in the literature, there
may be a benefit to thrombin inhibition with PPACK-NP, however this effect remains to be
delineated and is the subject of future studies with this therapeutic.
Current recommended systemic strategies for post-stent therapy include anticoagulation
and antiplatelet therapy. There has been considerable interest in modification of the implant itself
with strategies including coatings, surface modifications, and techniques to more rapidly
endothelialize the surface. Specific anti-thrombotic surface modifications with the addition of
heparin and bivalirudin have shown promise in prior studies.14,22 Of note, Zilver PTX was
recently approved and is the first drug-eluting stent approved for treatment of peripheral arterial
disease.23 Unfortunately, drug-eluting devices are plagued by early thrombosis and require
prolonged dual antiplatelet therapy with its attendant bleeding risks and costs. Our approach
offers a flexible method to employ a potent biocompatible nanoparticle that is functionalized
with > 10,000 copies of a relevant anticlotting agent per particle, which could be PPACK in this
case, or any other moiety as we have shown already for bivalirudin.8
The study has some limitations that merit discussion. As this is an in-vitro experiment
with controlled variables, these results cannot be immediately extrapolated to similar efficacy in
in-vivo models or in patients, where flow conditions may differ. Additionally, in the static
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experiment the clots were followed out to 60 minutes, but to more accurately depict clinical
situations more prolonged observations would be needed. Furthermore, bare metal stents are less
commonly employed clinically and the effect of these NPs on drug eluting stents will require
examination. Finally, persistence of the agent at the site of stenting or vessel injury will need to
be assessed.
Overall, this study has shown that anti-thrombin perfluorocarbon nanoparticles can
inhibit stent thrombosis in static and flow loop in-vitro models. Future work will explore efficacy
in vivo using rabbit models of thrombosis following vascular device implantation to validate the
promise of a potentially safer adjunctive solution to the clinical problem of intravascular stent
thrombosis.
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Figure 3-1

Figure 3-1: (A) Schematic of perfluorocarbon nanoparticle with surface conjugated PPACK
(PPACK-NP). (B) Following implantation, activated thrombin adsorbs to vascular stents forming
a pro-thrombotic coating. PPACK-NP binds to and inactivates this adsorbed thrombin
transforming the stent surface with a functionally anti-thrombotic coating.

87

Figure 3-2

Figure 3-2: (A) S-2238 incubation confirms thrombin adsorption to stent surfaces. (B) Incubation
of treated stents with platelet poor plasma results in significant clot deposition following 60
minutes of exposure with non-inhibitor treated stents compared to lack of clot growth on
PPACK-NP treated stents. (C) Rapid thrombus deposition following 5 minutes of platelet-rich
plasma exposure, compared to no growth on PPACK-NP treated stents for the duration of the
experiment. (D) Pretreatment with vorapaxar demonstrates little benefit in preventing stent
thrombosis alone, with significantly less clot deposition when used in combination with PPACKNP. (E) Ultrasound imaging of platelet poor plasma exposed stents confirms lack of clot
deposition on PPACK-NP treated stents compared to saline controls. In all panels, *p<0.05,
**p<0.005, ***p<0.0005.
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Figure 3-3

Figure 3-3: Scanning electron microscopy of platelet rich plasma exposed stents treated with (A)
Saline, (B) Control NP, (C) free PPACK, and (D) PPACK-NP. Stents treated with saline or
control NP show deposition of a dense fibrin mesh compared to PPACK or PPACK-NP treated
stents. SEM confirms the deposition of PPACK-NP on the stent surface with a measured
diameter of 185.46 ± 2.92 nm.
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Figure 3-4

Figure 3-4: Picrosirus red staining of thrombosed stents following 10 minutes of stent exposure
to flowing plasma containing each treatment group and 10 units of thrombin. In saline and
control NP treated plasma, occlusive thrombi were deposited on stents with minimal deposition
on stents in PPACK and PPACK-NP treated plasma.
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Figure 3-5

Figure 3-5: Thrombin inhibition allows for maintenance of normal cell viability and proliferation
in human aortic endothelial cells compared to non-inhibitor controls. In saline and control NP
treated groups, proliferation of endothelial cells was significantly decreased compared to
baseline levels of proliferation following 4 days of thrombin exposure.
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Chapter 4: Quantifying Progression and Regression of
Thrombotic Risk in Experimental Atherosclerosis with
Perfluorocarbon Nanoparticles
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Chapter Overview
Currently, there are no generally applicable noninvasive methods for defining the
relationship between atherosclerotic vascular damage and risk of focal thrombosis. Herein, we
demonstrate methods to delineate the progression and regression of vascular damage in response
to an atherogenic diet by quantifying the in vivo accumulation of semipermeable 200-300 nm
perfluorocarbon-core nanoparticles (PFC-NP) in ApoE null mouse plaques with 19F magnetic
resonance spectroscopy (19F MRS). Permeability to PFC-NP remained minimal until 12 weeks
on diet, then increased rapidly following 12 weeks, but regressed to baseline within 8 weeks after
diet normalization. Markedly accelerated clotting (53.3% decrease in clotting time) was observed
in carotid artery preparations of fat fed mice subjected to photochemical injury as defined by the
time to flow cessation. For all mice on and off diet, an inverse linear relationship was observed
between the permeability to PFC-NP and accelerated thrombosis (p = 0.02). Translational
feasibility for quantifying plaque permeability and vascular damage in vivo was demonstrated
with clinical 3T magnetic resonance imaging of PFC-NP accumulating in plaques of
atherosclerotic rabbits. These observations suggest that excessive permeability to PFC-NP may
indicate prothrombotic risk in damaged atherosclerotic vasculature, which resolves within weeks
after dietary therapy.
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4.1 Introduction
Atherosclerosis is the leading cause of death in the developed world, manifesting high
morbidity and mortality as a consequence of recurrent acute vascular events that are essentially
unpredictable in individuals and frequent despite maximal medical therapy.1,2 Recent focus on
the pathophysiology of atherosclerosis has shifted to the panoply of inflammatory cell types and
necrotic debris that engage a host of prothrombotic signaling events resulting in acute focal
clotting and vascular obstruction, unstable angina, and infarction.3,4 In territories prone to plaque
development, early lesion formation initiates with the development of a proinflammatory
endothelium, characterized by weakened tight junctions (<20 nm) that permit the passage of
small molecule dyes (e.g. Evans Blue)5,6 and albumin7-9. Noninvasive delineation of these very
early pathophysiological features that emerge well before clinical events arise has been available
for years with application of numerous imaging techniques that appear to presage an increased
incidence of events, at least in study populations that harbor traditional coronary risk factors.10,11
We recently reported a magnetic resonance imaging (MRI) and spectroscopic (MRS)
approach for delineating the severity of vascular endothelial damage in atherosclerotic vessels by
measuring the passive permeation of perfluorocarbon nanoparticles (PFC-NP) into plaques of
fat-fed rabbits after only 60-120 minutes of circulation in vivo. 12 Endothelial apoptosis, erosions,
and fibrin deposition were observed in these plaques after 6 months on a high cholesterol diet. Ex
vivo fluorine (19F) MRI and MRS depicted the intimal localization and quantity of PFC-NP in
rabbit atherosclerotic lesions that appeared after 6 months on diet, and also in diseased human
carotid endarterectomy samples that were incubated ex vivo with the PFC-NP. However, the
related clinically relevant question as to whether increased vascular permeability to PFC-NP in
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damaged vessels is correlated with focal prothrombotic risk in genetically-prone models of
vascular disease has not been examined.
Accordingly, we sought to answer the following questions: 1) whether prolonged feeding
of Western Diet induces a state of increased vascular permeability in ApoE null mice that can be
detected and quantified with the use of magnetic resonance spectroscopic and imaging methods;
2) whether the permeability of the endothelium to PFC-NP resolves following cessation of a
Western Diet and if such phenomena can be tracked and quantified with PFC-NP imaging
methods, and 3) whether vessel thrombotic risk is related directly to diet-induced vascular
permeability and how quickly accelerated thrombosis might resolve following Western diet
cessation.
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4.2 Materials and Methods
4.2.1 Nanoparticle Formulation
Fluorescent perfluorocarbon nanoparticles were formulated according to previously
established emulsification techniques.12 Briefly, the PFC-NP consisted of a 20% (vol/vol)
perfluoro-15-crown-5-ether (CE) core, 2% (wt/vol) surfactant, 1.7% (wt/vol) glycerin, and water.
The surfactant consisted of 98.8 mol% egg phosphatidylcholine, EPC (Lipoid, Newark, NJ), 1
mol% 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, DPPE (Avanti Polar Lipids,
Alabaster, AL) and 0.2 mol% 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine
rhodamine B sulfonyl), Rhodamine-PE (Avanti Polar Lipids, Alabaster, AL). The emulsion was
modified to replace the crown ether core with perfluorooctylbromide (PFOB) for use as a 19F
MRS reference standard for quantification of nanoparticle concentration in plaques. For in vivo
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F MRI studies in rabbits, the emulsion was modified to increase the perfluorocarbon and

surfactant content to include 4% (wt/vol) surfactant and 40% (vol/vol) CE.
4.2.2 Animal Experimental Model
Mouse feeding regimen: To produce aortic plaques, groups of male 4 to 6-week-old
ApoE-null mice were fed either normal chow or Western diet (TD-88137, Harlan Laboratories,
Madison, WI) for 2, 3, 4, 5, and 6 months. Two other sets of mice were fed with Western diet for
4 months and then switched to normal chow for either 1 or 2 months, thus serving as
experimental “off-diet” time points age-matched with mice continued on Western diet for 5 or 6
months. At each selected time point, a 1 ml/kg bolus dose of nanoparticles was administered via
tail vein injection and allowed to circulate for 2 hours 12 to allow for saturation of nanoparticle
accumulation in plaques.
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Carotid artery thrombosis procedure: Following 2 hours of in vivo nanoparticle
circulation, mice were anesthetized with a cocktail of ketamine and xylazine (87 mg/kg and 37
mg/kg, respectively) and subjected to photochemical injury of the carotid artery13-15 to determine
time to vessel occlusion. The right common carotid artery was exposed through a midline
cervical incision and blood flow rate was monitored using an ultrasonic Doppler probe
(Transonic Systems Inc., Ithaca, NY). The intended injury site was illuminated with a 1.5 mW
540 nm HeNe laser, followed by injection of 50 mg/kg Rose Bengal (Sigma-Aldrich, St. Louis,
MO) in saline to initiation of thrombus growth. The experiment was concluded upon upon
achieving a >85% decrease in carotid blood flow rate maintained for >5 min. Time to occlusion
was recorded and used to evaluate coagulability. Mice were then sacrificed and the aortas were
cleaned and removed for 19F spectroscopic evaluation of nanoparticle accumulation.
Rabbit feeding regimen: Male New Zealand White rabbits were maintained on an 0.25%
cholesterol feed (Cat. 9433, TestDiet, St. Louis, MO) for 9 months. For control images without
plaque development, young rabbits were fed normal chow. Both control and atherosclerotic
rabbits were anesthetized and given a 1ml/kg intravenous bolus of nanoparticles 2-3 hours prior
to 19F MRI.
4.2.3 19F Magnetic Resonance Spectroscopy
Fluorine magnetic resonance spectroscopy (MRS) was utilized to quantify nanoparticle
accumulation in aortic plaques ex vivo. 19F MRS was performed on an 11.7T Varian MR scanner
with a custom-built single-turn solenoid RF coil, with the following parameters: TR = 2.5 s,
1024 signal averages, with a scan time of ~42 minutes. A fluorine reference standard of 0.1%
PFOB emulsion was included with each aorta sample. To quantify plaque accumulation of crown
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ether nanoparticles, crown ether signal was compared to the distinct signal of the known PFOB
standard. The amount of crown ether nanoparticles was normalized to the weight of the aorta
sample.
4.2.4 Aortic Perfusion of PFC-NP and 19F Magnetic Resonance Imaging Ex Vivo
Aortas from rabbits fed a cholesterol diet for 8 months were excised and cannulated with
stub adapters for attachment to a custom-built perfusion system. The perfusion system consisted
of a variable flow rate perfusion pump (Cole Parmer, Barrington, IL) with Masterflex tubing
connected to stub adapters at either end of the vessel. A 50 ml conical tube served as a reservoir
for the perfusate, containing a 1:20 dilution of PFC-NP in saline. The diluted PFC-NP mixture
was perfused through the arteries at a flow rate of 30 mL/min for 4 hours. Following perfusion,
the isolated aortas were rinsed and fixed in 10% Formalin for 24-48 hours.
Ex vivo 19F spectroscopy of isolated aorta was performed on an 11.7T Varian scanner
(Varian Inc, USA). Prior to ex vivo 19F imaging, the vessel lumen was filled with 2% agarose gel
and stored in saline. Upon MRI, aortas were placed in a 1-cm tube filled with saline. A capillary
tube containing diluted (1:200) CE NPs were attached to the tube wall to serve as the external
signal standard. All images were acquired using a solenoid radio-frequency coil and a standard
fast-spin echo sequence. The coil was first tuned to 1H frequency to acquire a set of multi-slice
1H images. Imaging parameters were: field of view, 2 x 2 cm2; image matrix, 128 x 128; slice
thickness, 2 mm; number of slices, 11; TR, 2s; TE, 20ms, etl, 8; number of averages,4; imaging
time, 2 min. The coil was then tuned for 19F MRI. A set of 19F images was acquired at the
same location as 1H images. Imaging parameters were: field of view, 2 x 2 cm2; image matrix,
32 x 32; slice thickness, 2 mm; TR, 1.2s; TE, 20ms, etl, 8; number of averages, 4096; imaging
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time, 5 hour 28 min. The acquired 19F images (matrix size = 32 x 32) were interpolated to
128x128 and overlaid on corresponding 1H images to localize 19F signal of PFC NPs.
4.2.5 In vivo 19F Magnetic Resonance Imaging
To image the aortic wall for detection of nanoparticles permeating into the plaque intima,
we employed a 3T clinical whole-body scanner (Achieva, Philips Healthcare, The Netherlands),
outfitted with a dual 19F/1H spectrometer system.16 A dual-resonant 19F/1H surface RF coil was
used (15×15 cm), which can either transmit or receive at both resonance frequencies
simultaneously.17 Imaging was performed ~2h post-injection of 1.0 ml/kg PFC-NP with
perfluoro-15-crown-5-ether (PFCE; C10F20O5) core as previously described. To avoid signal
contamination from inhaled fluorinated anesthesia, a xylazine (10mg/kg) / ketamine (85 mg/kg)
i.m. injection was used for anesthesia induction, which was maintained with a ketamine i.v.
infusion (18 mg/kg/hr). A 2D simultaneous 19F/1H gradient echo (FFE) sequence was used with
the following parameters: FOV = 128×128 mm, matrix = 96×96, slice thickness = 20 mm, voxel
size = 1.33×1.33×20 mm, α = 25°, exBW = 5 kHz centered on single PFCE peak, pBW =
500 Hz, TR/TE = 14/1.72 ms, 1000 NSA, and a scanning time of 33 minutes. Saturation bands
proximal and distal to the imaging slice were applied to eliminate 19F signal from the blood pool.
The imaging slice was centered on the abdominal aorta, located 2-3 cm distal to the renal artery
via an angiogram consisting of a multi-2D time-of-flight gradient echo sequence with the
following parameters: FOV = 100×78 mm, matrix = 112×112, slice thickness = 2 mm, α = 60°,
TR/TE = 13.54/4.06 ms, 4 NSA, and a scanning time of 3 minutes. After anatomical
colocalization of 19F signal was confirmed with the simultaneously acquired 1H image, a highresolution gradient echo 1H image was used to display the overlaid 19F signal with the following
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parameters: FOV = 128×128 mm, matrix = 256×256, slice thickness = 4 mm, voxel size =
0.5×0.5×4 mm, α = 35°, TR/TE = 25.16/7.02 ms, 23 NSA, and a scanning time of 2.5 minutes.
4.2.6 Scanning Electron Microscopy
Freshly harvested aortas from ApoE-/- mice fed a high fat diet for 6 months were speed
vacuum dried overnight to allow visualization of superficial cholesterol crystals.18 Dried tissues
were then mounted for imaging. Scanning electron microscope images were acquired with
Hitachi S-2600H and FEI Nova Nano 2300.
4.2.7 Histology
For immunofluorescent evaluation of CD31 and thrombin deposition, mouse aortas were
harvested and embedded in optical cutting temperature (OCT) medium. Aortas were sectioned
and stained with either an anti-CD31 antibody (ab28364, Abcam Inc., Cambridge, MA) or an
anti-thrombin antibody (ab92621, Abcam Inc., Cambridge, MA). For Oil Red O staining of
rabbit aortas, tissue was embedded in OCT medium and sectioned. Slides were fixed in formalin,
and then stained in freshly prepared Oil Red O solution followed by rinsing with 60%
isopropanol. Sections were stained with hematoxylin, rinsed, then mounted for microscopy.
4.2.8 Two-Photon Imaging
Aortas were removed from both the normal chow and high cholesterol fed rabbits and
incubated en face for 15 minutes with 500 kD FITC-dextran to allow for ex vivo penetration of
the FITC-dextran into plaques. The imaging of the aorta samples was performed on a custombuilt video rate two-photon microscope19 equipped with a Chameleon Vision II Ti:Sapphire laser
(Coherent, Santa Clara, CA) in the Washington University in St. Louis School of Medicine In
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Vivo Imaging core. Fluorescence emission was passed through 480 nm and 560 nm dichroic
mirrors placed in series and detected as red (>560 nm), green (480 to 560 nm), and blue
(<480nm) channels by three head-on multi-alkali photomultiplier tubes.
4.2.9 FACS analysis of PFC-NP Uptake by Peripheral Blood Leukocytes and Splenocytes
Mice were injected i.v. with 200µl of nanoparticles and sacrificed 30 min later.
Leukocytes were isolated from mouse spleens and peripheral blood with Histopaque-1119
according to manufacturer's protocol (Sigma, St. Louis, MO). Antibodies against the following
molecules coupled to the indicated fluorochromes were used from BD Pharmingen (San Jose,
CA), eBioscience (San Diego, CA) or BioLegend (San Diego, CA): FITC anti-Ly-6C (HK1.4;
BioLegend), PerCP anti-Ly6G (1A8; BD Pharmingen), APC anti-F4/80 (BM8; eBioscience),
APC anti-TCRβ (H57-597; eBioscience), FITC anti-CD19 (1D3; BD Pharmingen). In general,
106 cells were blocked with the anti-FcR mAb 2.4G2, stained with the indicated Abs for 20 min
at 4°C and then washed and resuspended for FACS analysis. Flow cytometry was performed on
the BD FACSCalibur™. Data analysis was performed using BD CellQuest™ Pro software.
4.2.10 Western Blot Analysis of Complement Activation
Western blot analysis of complement activation was performed as described previously.20
C57BL/6 mice were injected intravenously with 10 µl/g of PBS, plain PFC-NP, and two different
species of gadolinium (Gd) loaded PFC (Gd-DTPA and Gd-DOTAP). Gd-DOTAP PFC-NP were
utilized as a positive control for complement activation. Thirty minutes following administration
of test doses, the mice were sacrificed and blood was collected via the inferior vena cava in
EDTA-loaded tubes. Blood samples were centrifuged for 5 min at 4˚C to obtain plasma samples.
For each sample, 15 µl of plasma was diluted 1:100 in SDS running buffer and fractionated by
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SDS-PAGE under reducing conditions to observe complement activation in plasma. For probing
of complement activation on the nanoparticle surface, blood samples were centrifuged at 960g
for 15 min, and the resulting pellet was rinsed four times in EDTA buffer, resuspended in SDS
running buffer and fractionated under reducing conditions with SDS-PAGE. In both plasma and
NP-surface analysis, complement activation was probed using anti-C3 (1:10,000 dilution,
Valeant Pharmaceuticals International, Aliso Viejo, CA) and anti-Factor H (1:1000 dilution,
CompTech, Tyler, TX) primary antibodies. The secondary antibody used was a horseradish
peroxidase-conjugated donkey anti-goat IgG (1:10,000 dilution, Jackson ImmunoResearch
Laboratories, West Grove, PA). The resulting bands were visualized with a SuperSignal West
Pico chemiluminescent substrate (Pierce, Rockford, IL).
4.2.11 Statistics
All statistical tests were performed on R, version 3.0.1. Carotid artery occlusion time data
was analyzed using Mann-Whitney-Wilcoxon rank sum test. Nanoparticle accumulation
trendline analysis was accomplished using a Student’s t test. The Pearson’s product-moment
correlation test was utilized to determine the relationship between nanoparticle accumulation and
carotid occlusion time. An ANCOVA was performed for analysis of cholesterol, nanoparticle
accumulation and carotid occlusion time data. For all statistical tests, p<0.05 denotes statistical
significance. Error bars denote standard error of the mean.
4.2.12 Study Approval
All procedures were performed with approval from the Washington University Animal
Studies Committee.
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4.3 Results
4.3.1 Functional evaluation of vascular permeability after prolonged Western Diet
To elucidate vascular permeability in vivo in ApoE null mice subjected to selected
durations on a Western diet, PFC-NP were injected i.v. and allowed to circulate for 2 hours prior
to excising whole aortas for 19F-MRS quantification of PFC-NP. A progressive monthly increase
in PFC-NP accumulation was observed in the atherosclerotic aortas of mice on Western diet over
and above that of mice on normal chow diets, the severity of which reflected the duration of
Western diet feeding (Fig. 4-1A). Prior to 3 months of feeding, little accumulation of PFC-NP
was observed in either Western diet fed or normal chow groups. However, beyond 3 months,
increased accumulation of PFC-NP was noted in aortic plaques of fat fed mice as compared with
the normal chow group, with plaque concentrations of PFC-NP reaching 0.201 ± 0.043 µl/g aorta
(N=3) in mice fed a Western diet for 6 months compared to the age-matched group of ApoE null
mice fed normal chow (0.081 ± 0.011 µl/g aorta, N=3).
4.3.2 Tracking regression of vascular permeability to PFC-NP
To delineate the resolution of endothelial permeability after dietary cholesterol reduction,
two additional groups of ApoE null mice were fed a Western diet for 4 months and then switched
to normal chow for either 1 or 2 months before injecting PFC-NP for spectroscopic evaluation of
vascular permeability. Serum cholesterol levels confirmed the effect of dietary replacement, as
cholesterol levels rose to 965.45 ± 201.05 mg/dl by 5 months in mice on Western diet compared
to 403 ± 39.69 mg/dl and 461.77 ± 45.15 mg/dl for mice on Western Diet for 4 months and then
off the Western diet for 1 month or 2 months, respectively (Fig. 4-1B). During this period, no
perceptible change in gross aortic plaque coverage was observed between experimental “off106

diet” groups and age-matched Western diet groups (data not shown). Regression of vascular
permeability was confirmed by a dramatic decrease in nanoparticle accumulation in mouse aortas
by two months after dietary cholesterol lowering (0.065 ± 0.019 µl/g aorta, N=4, p = 0.0009 vs
age-matched Western diet group), returning to age-matched ApoE null normal chow fed control
levels (p = NS). (Fig. 4-1A). Trend assessment from 4-6 months was performed by regression
analysis and demonstrated a significant difference in the slope of the linear fit between the
continued progression of vascular permeability in the Western diet fed mice versus the resolution
of vascular permeability in those mice removed from the diet (slope: 0.033 ± 0.019 vs -0.026 ±
0.009 for the Western diet group and the mice removed from Western diet, respectively; p =
0.015).
4.3.3 Relationship between vascular permeability and vessel thrombotic potential
As increased endothelial permeability and loss of endothelial cells has been linked to
future thrombotic events, we anticipated that potential differences in vessel thrombotic potential
might be related to the severity of permeability. Our hypothesis was further supported by the
presence of large deposits of intraplaque thrombin (Fig. 4-2A) that may contribute to the
generation of local inflammatory and procoagulant functions. Therefore, a standard model of
photochemical injury to the carotid artery was used to quantify the propensity to focal
thrombosis for the different diet schedules according to the time required to attain complete
vessel occlusion, which is inversely related to local procoagulant activity. Vessel injury in ApoE
null mice on normal chow for 5 months resulted in an occlusion time of 72.14 ± 5.02 min
(N=10), which was equivalent to that previously observed for wild-type C57BL/614: 69.06 ± 5.66
min, N=6; p=NS (Fig. 4-2B, red dashed line). ApoE null mice fed with Western diet for 5
months exhibited dramatically shortened occlusion times of 33.62 ± 3.04 min (N=6) as compared
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with the mice on normal chow (N=10) for 5 months (p = 0.004). In mice fed a Western diet for 4
months followed by normal chow for either 1 or 2 subsequent months, occlusion times
progressively lengthened back to control levels: 45.33 ± 5.63 min, N=7 (p = 0.005 vs. control)
and 68.6 ± 10.79 min (p=NS vs. control), respectively. (Fig. 4-2B) By 2 months after cessation
of Western diet, the occlusion time (68.6 ± 10.79 min, N=5) was not significantly different as
compared with wild-type C57BL/6 mice, indicating reversible diet-dependent vessel
procoagulant activity. Furthermore, occlusion time measurements on ApoE-/- mice fed a
Western Diet for 1 month (65.73 ± 23.65, N=3) were not significantly different compared to
wild-type C57BL/6 or normal chow ApoE controls. Importantly, an inverse correlation (Fig. 4-3)
was observed between nanoparticle accumulation and occlusion time (p = 0.02), indicating that
thrombotic potential tracks with increased vascular permeability in this model. Additionally,
ANCOVA analysis demonstrated no significant effect of serum cholesterol levels on carotid
occlusion time (p = 0.3849) and no significant interaction effect between serum cholesterol
levels and plaque nanoparticle accumulation (p = 0.4223), ruling out an independent effect of
blood cholesterol itself on occlusion times.
4.3.4 Mechanisms of intimal permeation of nanoparticles
To investigate potential mechanisms of nanoparticle penetration and retention, mouse
aortic tissue samples were imaged with scanning electron microscopy to examine the
morphology of intimal plaques. In accord with prior reports in rabbit12 and human18
atherosclerosis specimens that manifest superficial deposits of protruding cholesterol crystals
when properly prepared for SEM, we also observed analogous intimal and superficial cholesterol
crystals on samples of mouse aortas presenting with plaques (Fig. 4-4A-C). Immunofluorescent
staining of CD31 (Fig. 4-4D-F) revealed barely detectable intra-plaque signal, consistent with
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prior reports of limited angiogenesis at these earlier time points in atherosclerotic mice,
suggesting that passive diffusion of PFC-NP into the intima did not occur through neovascular
elements.21
To better define the potential route of intimal penetration of these PFC-NP into plaques,
we resorted to the previously validated rabbit model12 for two-photon assessment of
permeability. Rhodamine-labeled PFC-NP were administered to rabbits fed either normal or
high cholesterol chow. Aortic segments were removed from the rabbits following 2 hours of in
vivo nanoparticle circulation and incubated with FITC-dextran ex vivo, demonstrating prominent
accumulation of both FITC-dextran and PFC-NP beyond the lumenal surface of the plaque (Fig.
4-5), which is consistent with prior conclusions that active transport and blood flow are not
required to achieve intimal nanoparticle penetration. Furthermore, excised atherosclerotic rabbit
aortas were perfused ex vivo with PFC-NP on a custom built perfusion system for 4 hours to
elucidate the contribution of passive lumenal permeation of NP without the need for active
cellular transport or trafficking through vasa vasorum. Fluorine imaging of nanoparticle perfused
aortas (Fig. 4-6) demonstrates ample plaque-associated nanoparticles due to passive permeation.
To further rule out alternative cellular transport mechanisms, FACS analysis of isolated
peripheral blood leukocytes (PBL) (Fig. 4-7A) and splenocytes (Fig. 4-7B) collected 30 minutes
after i.v. injection of PFC-NP demonstrated minimal active uptake of the circulating PFC-NP by
cell types that might traffic to plaques: 0.26% of PBL and 0.93% of splenocytes. Western blot
analysis revealed no complement activation in response to the administration of nanoparticles,
militating against immune cell trafficking of complement activated PFC-NP (Fig. 4-8).
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4.3.5 Imaging nanoparticle plaque permeation in vivo
In a pilot study, 19F MRI was performed on rabbits with or without diet-induced
atherosclerotic plaques (Fig. 4-9). Figures 5A and D are proton images of abdominal crosssections showing the position of the aorta in rabbits fed normal chow and Western diet,
respectively; 5B and E are the fluorine-only signatures after PFC-NP circulation in vivo for 180
minutes. Note the excellent suppression of lumenal blood 19F signal in the normal chow rabbits
due to saturation band placement (Fig. 4-10) indicating that no signal arises from the circulating
PFC-NP. Figures 4-9C and 4-9F are 19F/1H overlays showing the aortic and adjacent vena cava
wall 19F signals (green) emanating from PFC-NP permeating into arterial plaques, and
interestingly into adjacent inflamed venous structures that can accumulate PFC-NP when
subjected to the same hyperlipidemic drive.22,23 Figure 4-9C demonstrates that in a healthy
rabbit, no measurable nanoparticle retention occurs in the aorta or vena cava. Corresponding Oil
Red O staining of the imaged area (Fig. 4-9G-H) confirmed the presence of aortic plaques, or
lack thereof.
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4.4. Discussion
Herein we describe for the first time a quantitative in vitro and in vivo MRI/MRS
approach for delineating the progression and/or regression of atherosclerotic vascular damage
that bears a direct relationship to focal thrombotic risk. The use of 19F MRS/MRI enables
quantification of plaque permeability as a consequence of vascular damage induced by Western
diet according to measured plaque PFC-NP content (Fig. 4-1A). It is notable here that we
employed the entire aorta to ensure an objective definition of vascular permeability that avoided
any potentially subjective bias of segmental selection. We observed a marked acceleration of
endothelial permeability after 12 weeks on a Western diet in ApoE null mice, greatly exceeding
that of mice maintained on normal chow. Rapid diminution of permeability to PFC-NP to
baseline levels was achieved after only 2 months of dietary management, where ANCOVA
analysis demonstrated no significant interaction effect (p = 0.4223) of serum cholesterol levels
on endothelial permeability, suggesting that some feature of, or response to the dietary regimen
other than just serum cholesterol level may have contributed to the observed vascular damage.
Furthermore, we observed a concomitant rapid resolution of the vascular prothrombotic
state in ApoE null mice after only 2 months of dietary management. A standard experimental
method was used to quantify vessel thrombotic potential by inducing occlusive thrombosis in the
carotid artery with Rose Bengal dye and laser injury that operates by generating caustic
superoxide anions, which are known to contribute to the pathogenesis and progression of
atherosclerosis.24 We observed that the functional MRI/MRS readouts for vascular permeability
were correlated with the severity of prothrombotic risk (Fig. 4-3) as measured by time to total
occlusion of the carotid artery after photochemical injury. Furthermore, we found that these
correlated measures of vascular permeability and accelerated thrombosis resolve concomitantly
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and rapidly to baseline values after dietary normalization. One potential caveat to note here is
that the occlusion times were measured in the carotid artery territory, whereas the permeability
metrics were acquired from the entire unselected aorta because experimentally it was not
possible to acquire both data sets from the same vascular region in a given animal. However,
because the disease process is clearly diffuse and progressive, even though some local
differences in plaque severity may pertain, the correlative assessment should be informative as to
the overall state of the disease process, especially in light of the rapid resolution of both metrics
after cessation of the Western diet.
The use of ApoE null mice for the quantification of vascular barrier damage with PFCNP was advantageous because immunofluorescent staining of aortic plaques for CD31 in our
mouse model revealed little intra-plaque neovasculature up to 6 months of continuous Western
Diet (Fig 4-4D-F). Prior reports of angiogenesis in mouse plaques as measured by CD31 staining
indicate the presence of neovasculature only after 9 months of cholesterol feeding21. Lack of
plaque neovasculature at our measured time points, in concert with evidence of cholesterol
crystals perforating the intima of diseased ApoE null mouse aortas (Fig 4-4A-C), suggests that
lumenal entry of PFC-NP through highly permeable endothelial barriers may be the prevailing
route of nanoparticle penetration and retention, rather than through vasa vasorum or
neoangiogenic routes. However, it is important to note that vasa vasorum/neoangiogenic delivery
of nanoparticles may be possible in larger subjects such as rabbits and humans. Our current data
utilizing ex vivo nanoparticle perfusion of atherosclerotic rabbit aortas (Fig. 4-6) coupled with
prior data utilizing human endarterectomy specimens12, suggests that lumenal entry of
nanoparticles remains a significant contributor to nanoparticle signal. Furthermore, the likelihood
of predominantly lumenal entry and retention of PFC-NP in plaques accords with our prior work
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in atherosclerotic rabbits that showed that PFC-NP do not gain access to the intima of
atherosclerotic vessels through neoangiogenic routes in early atherosclerosis,25 but may enter
through eroded endothelium in later stages of plaque development.12 Additionally, investigations
of alternative routes of plaque accumulation of PFC-NP through assays for complement
activation (Fig. 4-8) or through FACS analysis of nanoparticle uptake in circulating cells (Fig. 47) suggests that active trafficking of peripheral blood leukocytes and/or splenocytes harboring
PFC-NP is unlikely in this short experimental time window (<2 hours). 26,27 Thus, the detected
19

F signal is more probably a consequence of passive accumulation of PFC-NP entering through

a highly permeable or disrupted endothelial barrier rather than influx of PFC-NP bearing cells.
With respect to potential interpretations of these data in the light of classically described
endothelial dysfunction, we note that implications for endothelial dysfunction in the ApoE null
model are not especially well defined in a temporal and quantitative sense. Endothelial
dysfunction typically is depicted in terms of decreased endothelium-dependent vasodilation. The
time course of the development of endothelial dysfunction in ApoE null mice is somewhat
debatable, with various studies demonstrating differing responses to acetylcholine (ACh)induced vasodilation at selected time points after induction of hypercholesterolemia. Moreover,
some studies have even reported normal responses of the aortic endothelium at 20-30 weeks of
cholesterol feeding, as opposed to other studies demonstrating significant impairment at 14-15
weeks of cholesterol feeding.28 Thus, speculation as to whether enhanced PFC-NP permeation
represents classical endothelial dysfunction as contrasted with more severe endothelial damage
or death (e.g., erosions) cannot be supported by the present data set.
Nevertheless, it is clear that these data indicate the possibility of delineating thrombotic
risk by quantification of endothelial permeability to PFC-NP that are directly associated with
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structural damage to the endothelial lining of vessels where plaques have formed. Other groups
have previously explored noninvasive assessments of endothelial permeability in atherosclerotic
ApoE null mice at very early time points after fat feeding. For example, recent work by
Phinikaridou et al utilized the clinically approved albumin-binding contrast agent gadofosveset
(<6 nm diameter) for measurements of endothelial permeability as a consequence of early
endothelial dysfunction with MRI. In this work, MRI of mice on a high-fat diet demonstrated
accumulation of gadofosveset as early as 4 weeks after inception of a high-fat diet, which
correlated well with Evans Blue staining.8 These results are consistent with prior descriptions of
endothelial permeability of Evans Blue5,6 and albumin7 through weakened and/or broken tight
junctions. However, in our study at these earlier stages of atherosclerotic disease up to 12 weeks
of cholesterol feeding, the endothelium remains impermeable to the PFC-NP and there is no
significant increase in vessel hypercoagulability as measured by carotid occlusion times.
Together these observations suggest the appearance of more substantial structural changes in the
endothelial barrier of these large vessels, when junction widths increase to ~2-3 µm9 or greater as
a consequence of pathological features such as cholesterol crystal perforation (Fig. 4-4A-C) and
superficial plaque erosions that accord with markedly enhanced permeability over and above that
which might be observed with mild cell junction widening that is associated with classical early
measures of endothelial dysfunction.12 In support of this contention, it has been noted that as
atherosclerotic disease progresses, mechanical (i.e. cholesterol crystals29) and biological stressors
contribute to endothelial apoptosis and subsequent sloughing of endothelial cells, leaving a
disrupted or denuded endothelial barrier30 exposing large multi-micron diameter perforations in
the intimal lining, 12 and unfettered access of circulating blood elements to a reservoir of
inflammatory cell types, lipids, cytokines, and coagulation factors that enhance prothrombotic
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tendencies.31 These and prior data suggest that enhanced endothelial permeability to small
molecules within the first 3 months of high-fat diet feeding primarily reflects nanoscopic
expansion of cell-cell junctions in intact viable, but dysfunctional endothelium, whereas beyond
3 months of high-fat feeding, the endothelial permeability to PFC-NP might reflect more severe
vascular damage that would be more quantitatively depictive of a focal hypercoagulable state
than would endothelial dysfunction alone.
As prior pathological studies on victims of acute coronary syndromes have established
the clinical relevance of eroded or denuded plaques32,33, the ability to non-invasively image
endothelial permeability could have clinical relevance. In view of recent clinical reports by
Damani et al. of the association of plaque endothelial sloughing and acute vascular syndromes in
atherosclerotic patients10 and Makin et al, demonstrating increased CECs can be indicative of
endothelial damage in patients with severe atherosclerosis34, non-invasive evaluation of
endothelial barrier disruption that corresponds directly with local thrombosis potential could be
useful for detecting frank vascular damage and for depicting beneficial responses to cholesterol
lowering at the vascular tissue level.35 In light of these clinical reports, we investigated a
potential translatable methodology for in vivo delineation of endothelial permeability through
imaging of rabbits with or without atherosclerosis in a clinical 3T MRI scanner (Fig. 4-9)
outfitted for 19F detection. Our results suggest the ability to depict permeable plaques in vivo
after only ~2-3 hours of PFC-NP circulation (Fig. 4-9C). We note here that the voxel size
required for recording a sufficient 19F signal to enable fluorine MRI necessarily yields a
comparatively low resolution fluorine image in the rabbit (see Fig. 4-9B and 4-9E), as contrasted
with the higher resolution 1H image. Nevertheless, the ability to image voxels containing PFC-
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NP at 3T on a multispectral clinical scanner in rabbits suggests that this approach could be
implemented on clinical scanners.
Although endothelial dysfunction as currently measured is associated with risk of
eventual clinical events in large populations of selected patients36,37, it is not used routinely as a
harbinger of thrombotic potential in individual patients. Whether the present noninvasive
methods for quantification of endothelial damage and accelerated thrombosis have any value for
detecting plaque rupture or vulnerable plaque, at least as these entities are now defined, remains
conjectural because their evaluation in animal models is problematic.
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Figure 4-1

Figure 4-2: (A) 19F MRS demonstrating time dependence of nanoparticle accumulation in ApoE
null mouse aortas with or without a Western diet. Continuous Western diet feeding results in a
significant increase in nanoparticle accumulation over age-matched normal chow controls (†
denotes p = 0.003) Return to a normal chow diet restores control levels of nanoparticle
accumulation (‡ denotes p = 0.0009 vs age-matched Western diet group). "Off Diet" group at 6
months was not significantly different from age-matched normal chow controls. Trend analysis
on Western Diet and “Off Diet” groups following 4 months on diet demonstrates significant
difference in progression of nanoparticle accumulation (p=0.015). (B) Serum cholesterol values
for mice on normal chow for 5 months, on Western diet for 5 months, on Western diet for 4
months followed by 1 month or 2 months switched back to normal chow.
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Figure 4-2

Figure 4-2: (A) Immunofluorescent staining confirms abundant intra-plaque thrombin (green) in
mouse aortic plaques. Scale bar denotes 100 µm. (B) Return to normal chow progressively
increases carotid occlusion times to control values for both normal chow ApoE null mice
(leftmost bar) and wild-type mice (dashed line: based on prior published data14 (*p=0.0056,
**p=0.004, vs. control).
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Figure 4-3

Figure 4-3: Correlation plot of aortic nanoparticle accumulation and carotid occlusion time (R = 0.64, p = 0.02) demonstrating relationship between vascular permeability and thrombotic
potential.
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Figure 4-4

Figure 4-4: (A) SEM of cholesterol crystals densely deposited on surface of aortic plaque. Scale
bar: 100 µm (B) SEM of cholesterol crystals on denuded plaque (P) but not on adjacent regular
endothelium (E). Scale bar: 40 µm. (C) Higher magnification SEM depicts morphology of
cholesterol crystals. Scale bar: 20 µm. (D-F) Immunofluorescent staining for CD31 (green)
demonstrates little to no intraplaque angiogenesis in ApoE null fed a Western Diet for (D) 4
months, (E) 5 months, and (F) 6 months. Scale bars denote 50 µm.
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Figure 4-5

Figure 4-5: (A) Penetration of FITC-dextran (green) and PFC-NP (red) into a plaque is revealed
with 3-D two-photon microscopy imaging of en face atherosclerotic rabbit aortic tissue. (B)
Two-photon microscopy of en face normal rabbit aortic tissue. Scale bar: 50 µm. Tissue autofluorescence is shown in blue. (C) Sideview two-photon microscopy image of atherosclerotic
rabbit tissue demonstrating penetration of FITC-dextran (green) and PFC-NP (red) into plaques.
(D) Sideview two-photon microscopy image of normal rabbit tissue demonstrating lack of FITCdextran (green) and PFC-NP (red) penetration through intact tissue lumenal barriers. Scale bar:
50 µm.
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Figure 4-6

Figure 4-6: Fluorine magnetic resonance imaging of excised rabbit aorta at 11.7T following 4
hours of PFC-NP perfusion. (A) Proton image demonstrating intimal plaque deposition. (B)
Fluorine image confirms the presence of PFC-NP in the aorta sample. (C) Fluorine image
overlaid on the proton image demonstrates localization of PFC-NP in plaques. An external
standard (bottom left corner of all three images) allows for quantification of nanoparticle
concentration.
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Figure 4-7

Figure 4-7: (A) FACS analysis reveals minimal cellular active uptake of rhodamine-labeled PFCNP by 0.26% of circulating peripheral blood leukocytes. The RhodPE+ population comprises
Ly6C+Ly6G+ cells (myeloid cells) and a small number of CD19+ cells (B cells). (B) FACS
analysis reveals minimal active uptake of PFC-NP by 0.93% of splenocytes. The RhodPE+
population comprises F40/80+ and Ly6C+F4/80+ cells (monocytes/macrophages) and a smaller
percentage of CD19+ cells (B cells). T cells (TCRb+) do not take up PFC-NP.
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Figure 4-8

Figure 4-8: Assays for nanoparticle-dependent complement activation following 30 minutes of
nanoparticle circulation in mice (A) Western blot analysis of complement component 3 (C3)
cleavage in the plasma and on the nanoparticle surface. Administration of plain PFC-NP does not
initiate the generation of the C3α chain cleavage product, α2, on both the nanoparticle surface or
in the plasma. (B) Plasma and nanoparticle surface-bound Factor H was assayed, indicated no
recruitment of Factor H to the nanoparticle surface following plain PFC-NP administration.
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Figure 4-9

Figure 4-9: Cross-sectional 1H images at 3T of (A) normal chow rabbit and (D) cholesterol fed
rabbit showing location of abdominal aorta (red box). 19F gradient echo images of perfluoro-15crown-5-ether nanoparticle 19F signal in the region of interest for (B) normal chow rabbit and (E)
cholesterol fed rabbit. Saturation bands proximal and distal to imaging slice eliminate 19F signal
from blood (See Figure S5). 19F signal (green) overlaid on 1H image showing 19F signal
colocalization for the region of interest in a (C) normal chow rabbit and (F) cholesterol fed rabbit,
demonstrating deposition of PFC-NP only in inflamed abdominal aorta (AA) and vena cava
(VC). Representative Oil Red O stains of the imaged area showing plaque elements in the (G)
normal chow rabbit aorta and the (H) cholesterol-fed rabbit aorta. Scale bars denote 500 µm.
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Figure 4-10

Figure 4-10: Locations of saturation bands used to null fluorine signal from the blood pool. The
aorta, shown in red, was imaged with a time-of-flight angiogram.
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Chapter 5: Anti-Inflammatory and Endothelial Barrier
Protective Effects of PPACK-NP in Atherosclerotic Mice
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Chapter Overview
A role for thrombin in the pathogenesis of atherosclerosis has been suggested through
clinical and experimental studies revealing a critical link between the coagulation system and
inflammation. Although approved drugs for inhibition of thrombin and thrombin-related
signaling have demonstrated efficacy, their clinical application to this end may be limited due to
significant potential for bleeding side effects. Thus, we sought to implement a plaque-localizing
nanoparticle-based approach to interdict thrombin-induced inflammation and hypercoagulability
in atherosclerosis.
We deployed a novel magnetic resonance spectroscopic method to quantify the severity
of endothelial damage for correlation with traditional metrics of vessel procoagulant activity
after dye-laser injury in fat-fed ApoE-null mice. We demonstrate that a one-month course of
treatment with anti-thrombin nanoparticles carrying the direct thrombin inhibitor Dphenylalanyl-L-prolyl-L-arginyl chloromethylketone (PPACK-NP): 1) reduces the expression
and secretion of proinflammatory and procoagulant molecules, 2) diminishes plaque
procoagulant activity without the need for systemic anticoagulation, 3) rapidly restores disrupted
vascular endothelial barriers, and 4) retards plaque progression in lesion prone areas.
These observations illustrate the role of thrombin as a pleiotropic atherogenic molecule
under conditions of hypercholesterolemia, and suggest the utility of its inhibition with locally
acting anti-thrombin nanoparticle therapeutics as a rapid-acting anti-inflammatory strategy in
atherosclerosis to reduce thrombotic risk.
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5.1 Introduction
Atherosclerosis, the leading cause of death in the Western world, is essentially a disease
of inflammation from its inception through the evolution of vulnerable atheromas that eventually
break down to induce focally occlusive thrombosis with consequential tissue death in subtended
vascular beds.1 A direct link exists between inflammation and coagulation in atherosclerosis by
way of the serine protease thrombin that plays a central role in both clot formation and
inflammatory molecular signaling events that may instigate and potentiate plaque development.24

Thrombin's vascular activity is mediated primarily by a family of G-protein coupled receptors

known as protease-activated receptors (PARs).5 Activation of PAR-1 by thrombin initiates a
signaling cascade that promotes proinflammatory, vasomotor, and cellular proliferative effects in
various cell types, including endothelial cells, smooth muscle cells, and macrophages, among
others. Thrombin signaling promotes the synthesis and release of procoagulant factors such as
tissue factor, which establishes the conditions for repeated cycles of endothelial disruption,
coagulation, inflammation, and plaque expansion.6
Given the abundance of thrombin in atherosclerotic plaques and its recognized
contribution to plaque inflammation and hypercoagulability7,8, we sought to investigate the
hypothesis that focal inhibition of plaque thrombin to abrogate its inflammatory signaling actions
would both attenuate plaque procoagulant activity and facilitate restoration of naturally
anticoagulant endothelial vascular barriers. Furthermore, we sought to elucidate direct
relationships between thrombin inhibition, regulation of inflammatory signaling, recovery of
endothelial barriers, and reduction in thrombotic risk with the use of clinically translatable
functional methods for quantifying vascular barrier integrity. Although clinically approved antithrombotic pharmaceuticals have been evaluated in experimental primary and clinical secondary
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prevention trials9, no information exists as to their ability to directly attenuate focal plaque
thrombotic propensity or to improve vascular barrier integrity, which could serve to deter acute
vascular syndromes.
To those ends, we have reported recently that atherosclerotic endothelial damage can be
quantified nondestructively with the in vivo use of semipermeant perfluorocarbon-core
nanoparticles (PFC-NP) that passively diffuse beyond disrupted endothelial barriers in plaques,
allowing both fluorine magnetic resonance imaging and quantification of PFC-NP deposition
with fluorine magnetic resonance spectroscopy (19F-MRI and 19F-MRS, respectively).10 Using
this method, we have delineated the temporal progression of endothelial barrier disruption in
ApoE-null mice as a consequence of a prolonged high fat diet and demonstrated that barrier
damage was related directly to the propensity for thrombotic occlusion in the dye-laser vessel
injury model. Moreover, dietary management by restoration of a normal chow diet
simultaneously recovered vascular barrier integrity and rapidly reduced plaque
hypercoagulability within 1-2 months.11 Although these nanoparticles previously have been
conjugated to selected antithrombin agents to serve as potent and safe antagonists of thrombosis
in acute clotting events12,13, their therapeutic potential for chronic control of inflammatory
signaling through thrombin inhibition is untested in atherosclerosis.
Accordingly, we hypothesize that the reported capability of PFC-NP to localize to
atherosclerotic plaques manifesting disrupted barriers and be retained for prolonged periods10,11
would set the stage for the formulation and focal deposition of a reservoir of anti-thrombin
nanoparticles in plaques (Fig. 5-1A) to exert prolonged surveillance against and rapid
inactivation of any locally generated thrombin. The present work was designed to examine the
efficacy and safety of nanoparticle-based strategies for focal inhibition of thrombin (Fig. 5-1A)
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in atherosclerosis and to define related inflammatory signaling events in vitro and in vivo that
might play a mechanistic role in accelerating vascular endothelial barrier damage and thrombotic
risk. The observed efficacy of the approach indicates a significant direct contribution of thrombin
signaling to the evolution of atherosclerosis and the emergence of thrombotic risk, and implicates
it as a key contributor to endothelial damage in this model.
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5.2 Materials and Methods
5.2.1 Animal Model
To induce atherosclerosis in mice, 4-6 week old male ApoE-null mice (The Jackson
Laboratory, Bar Harbor, ME), were fed a Western diet (TD-88137, Harlan Laboratories,
Madison, WI) for 3 months continuously. Following 3 months of Western diet, mice were
continued on diet for 1 more month with treatments of either 1 ml/kg saline, control NP, or
PPACK-NP three times per week for a total of 12 doses (Fig. 5-1B). In animals used for plaque
permeability measurements, a 1ml/kg dose of crown ether (CE) NP was administered 2 hours
prior to sacrifice for single detection by MRI/MRS (see below). Blood was harvested from the
left ventricle and serum was submitted to the Washington University Department of Comparative
Medicine for cholesterol measurements.
5.2.2 Nanoparticle Formulation
PPACK-NP were formulated using previously described emulsification and conjugation
techniques.12 Briefly, NP were first formulated as carboxyl-terminated perfluorocarbon
nanoparticles composed of a 20% (vol/vol) perfluorooctylbromide (PFOB) core, 2% (wt/vol)
surfactant, 1.7% (wt/vol) glycerin, and water. The surfactant used in this formulation consisted
of 99% egg phosphatidylcholine, EPC (Avanti Polar Lipids, Alabaster, AL) and 1 mol% 1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000], DSPEPEG2000-COOH (Avanti Polar Lipids, Alabaster, AL). Following emulsification of the mixed
surfactant, PFOB, glycerin, and water, the resulting precursor nanoparticle was activated for
coupling of PPACK to the surface carboxyl groups with the use of 2 mg/ml 1-ethyl-3-(3dimethylaminopropyl carbodiimide HCl, EDC (Pierce, Rockford, IL). Amine coupling of
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PPACK to the nanoparticle was then completed with the addition of 12.5 mg/ml PPACK
(American Peptide Company, Sunnyvale, CA) to the activated precursor formulation following
overnight mixing. The conjugated nanoparticle formulation was then dialyzed against MilliQ
water with a MWCO of 3000-5000 for 4 hours with stirring. Size and zeta potential were
measured on a ZetaPlus analyzer (Brookhaven Instruments Corporation, Holtsville, NY) and
were determined to be 245.3 ± 3.5 nm and -6.13 ± 0.64 mV, respectively.
5.2.3 19F Magnetic Resonance Spectroscopy For Quantification of Nanoparticle Deposition in
Plaques
Fluorine magnetic resonance spectroscopy (19F-MRS) enables absolute quantification of
plaque endothelial barrier disruption (Fig. 5-1C) by measuring the deposition of fluorine-core
nanoparticles into aortic intimal plaques as described in previous work.10,11 There are several
practical advantages of this method over traditional staining approaches. The semipermeant 250
nm diameter PFC NP circulating in vivo provide a functional and selective metric for plaque
endothelial barrier damage as they do not penetrate adjacent vascular segments devoid of plaque.
Nor do they register the very early stages of endothelial dysfunction (e.g., weakening of tight
junctions), but rather correspond to a later stage of endothelial disruption that correlates directly
with procoagulant activity.11 The measurement is fully quantitative based on 19F spectroscopy,
and objective because an entire unprocessed aortic segment is utilized without need for
subjective selection of regions of interest or interpretation of selected microscopic sections.
Finally, the permeation of NP is entirely passive and does not involve cell trafficking after NP
uptake as it operates similarly ex vivo in excised and formalin fixed specimens.10,11
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Measurements were carried out on an 11.7T Varian MR scanner using a custom-built
single solenoid RF coil. All measurements were conducted with the following parameters in each
fluorine measurement: TR = 2.5s, 1024 signal averages, and a total scan time of ~42 minutes per
sample. A reference standard of 0.1% trifluoroacetic acid (TFA) was included in each aorta
sample to allow for absolute quantification of the perfluro-crown ether signal from the
nanoparticles compared to the known amount of TFA.14 For each sample, the detected amount of
nanoparticles was normalized based on the weight of the aorta.
5.2.4 Photochemical Injury of the Carotid Artery to Assess Vascular Procoagulant Activity
Mice were anesthetized with ketamine (87 mg/kg) and xylazine (37 mg/kg) followed by
isolation of the right common carotid artery through a midline cervical incision. A Doppler
ultrasound probe (Transonic Systems, Inc., Ithaca, NY) was placed on the carotid artery to
monitor blood flow rate for the duration of the experiment. Mice were administered a dose of
50mg/kg Rose Bengal (Sigma-Aldrich, St. Louis, MO) in saline to initiate thrombus growth
following illumination of the injury site with a 1.5 mW 540 nm HeNe laser. The injury procedure
concluded upon achieving a >85% decrease in measured carotid blood flow rate that was
maintained for >5 minutes, indicative of stable occlusion of the carotid artery. Time to carotid
occlusion was measured as a metric of coagulability where increased time to occlusion indicated
increased potential for coagulation (Fig. 5-1D).
5.2.5 Cell Culture
Human aortic endothelial cells (HAECs) were obtained from Lifeline Cell Technology
(Frederick, MD) and cultured in VascuLife EnGS Endothelial Cell Culture Medium (Lifeline
Cell Technology), which was composed of Vasculife Basal Medium supplemented with 0.2%
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Endothelial Cell Growth Supplement, rhEGF (5 ng/ml), ascorbic acid (50 µg/ml), L-glutamine
(10 mM), hydrocortisone hemisuccinate (1 µg/ml), heparin sulfate (0.75 U/ml) and 2% fetal
bovine serum (FBS). THP-1 cells were obtained from ATCC and cultured in RPMI-1640
supplemented with L-glutamine (300 µg/ml) and 10% FBS. Cells were used at passages 2-4 for
all experiments.
5.2.6 Inflammatory Signaling Events
PAR-1 Assay: A previously described method15,16 was utilized on HAECs to assay the
inhibition of PAR-1 activation by thrombin. HAECs were incubated with 10 nM human
thrombin (Haematologic Technologies, Essex Junction, VT) in assay medium (consisting of
Vasculife Basal Medium) supplemented with either PBS, 10 nM PPACK, 0.8 nM plain PFOB
NPs, or 0.8 nM PPACK NP for 2 hours with N=3 per group. The molar amounts of treatments
were determined based on a 1:1 ratio of thrombin to inhibitor. Following incubation of HAECs
with thrombin and each respective treatment group, HAECs were washed three times using PBS
without Ca2+ and Mg2+ followed by cell harvesting with Nonenzymatic Cell Dissociation
Solution (Sigma-Aldrich, St. Louis, MO). The harvested cells were washed and pelleted in
FACS Incubation Buffer (0.5% bovine serum albumin in PBS without Ca2+ and Mg2+), followed
by staining with a phycoerythin-labeled antibody against residues 35-46 of the PAR-1 receptor,
corresponding to the cleavage site of PAR-1 (SPAN12, Beckman-Coulter, Brea, CA) for 30
minutes. Following staining, cells were washed in FACS Incubation Buffer three times each
prior to and following fixation with 1% paraformaldehyde. Samples were analyzed on a BD
FACScan Analytic Flow Cytometer, with ten thousand events collected per sample. Data was
analyzed with FlowJo Collectors Edition.
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Surface Tissue Factor Activity Assay: To measure the activity of surface exposed tissue
factor on thrombin-activated cells, a functional assay of factor Xa generation was utilized.17
Cells were plated in 96 well plates at 30,000 cells per well and allowed to adhere overnight.
Following overnight acclimation, cells were exposed to thrombin at 1 U/ml or 4 U/ml in serumfree medium containing equimolar amounts of either saline, free PPACK, control NP or PPACKNP for 6 hours. Following stimulation with thrombin and each respective treatment, cells were
rinsed three times with TF Activity Assay Buffer containing 50 mM HEPES, 150 mM NaCl, and
5 mM CaCl2 at pH 7.5. Cells were then exposed to Factor VIIa (4 nM, Haematologic
Technologies) and Factor X (300 nM, Haematologic Technologies) in 150 µl of TF Activity
Assay Buffer for 30 minutes. Following factor VIIa/X incubation, the reaction conversion was
stopped with 5 µl of 100 mM EDTA. Generated Factor Xa was then assayed with the addition of
100 µl of 500 µM Chromogenix S-2222 (Diapharma, West Chester, Ohio), and allowed to
incubate for 20 minutes. Cleavage of S-2222 was stopped with 10 µl of 30% acetic acid and the
plate was then read at 405 nm on a BioRad Model 550 Microplate Reader.
NF-kB Assay: HAECs and THP-1 cells were seeded on to coverslips at 100,000
cells/coverslip. For THP-1 seeded coverslips, coverslips were treated with 0.01% poly-L-lysine
solution for 15 minutes, followed by 2 hours of drying prior to cell seeding. Following overnight
incubation to allow for cell attachment, cells were stimulated with either thrombin alone or
thrombin treated with PPACK, control NP, or PPACK-NP for 6 hours. Cells were then fixed
with 4% paraformaldehyde and permeabilized with 0.25% Triton X-100 in PBS. Cells were
stained for phosphorylated p65 and IkB as markers of NF-kB activation using a phospho-p65
primary antibody (1:200 dilution, ab28856, Abcam, Cambridge, MA) or an IkB primary
antibody (1:200 dilution, ab7217, Abcam) and and Dylight 488 secondary antibody (1:500
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dilution, ab96899, Abcam). Coverslips were mounted onto slides with DAPI loaded mounting
medium to counterstain for nuclei and cells were imaged using fluorescent microscopy.
TAT and sVCAM Assays: For measurements of thrombin-antithrombin (TAT)
complexes and soluble VCAM-1 (sVCAM-1), blood was harvested from the left ventricle and
serum was stored for ELISA analysis. TAT-complexes were measured on serum using an ELISA
kit (ab137994, Abcam) as per the manufacturers instructions. For sVCAM-1 measurements,
serum was assayed using an ELISA kit (MVC00, R&D Systems Inc., Minneapolis, MN) as per
the manufacturers instructions
5.2.7 Histological Analyses
For evaluation of gross plaque deposition in the aortic arch, aortas were removed a
pinned en face for staining of plaques with Sudan IV. Tissues were fixed in 10% formalin for 24
hours, then stained with Sudan IV. Quantification of positive fat staining was carried out in the
aortic arch for saline treated mice (N=5) and PPACK-NP treated mice (N=7) using ImageJ. Arch
segments were selected using the top 1/3 portion of the aorta and uniformity of segments for
analysis was verified through ImageJ measurements of total surface area for the region of
interest. For histological analysis of plaque characteristics, tissues were stored in in optical
cutting medium (OCT) and frozen sectioned at a thickness of 5 µm. Antibodies against Tissue
Factor (1:100 dilution, sc30201, Santa Cruz Biotechnology, Dallas, Texas), phospho-p65 (1:200
dilution, ab28856, Abcam), von Willebrand Factor (1:100 dilution, ab11713, Abcam), and
macrophages (1:100 dilution, ab33451, Abcam) where used to stain tissue sections.
Quantification of positive staining for tissue factor, phospho-p65 and macrophages was
accomplished using ImageJ with N=3 mice per treatment group.
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5.2.8 Activated Partial Thromboplastin Time
For measurement of activated partial thromboplastin time (APTT), blood was drawn from
the ventricle at the time of sacrifice into a syringe containing 4% sodium citrate for APTT
measurements at a final dilution of 1 part sodium citrate to 9 parts whole blood. Blood samples
were centrifuged for 15 minutes at 1000g and the supernatant was saved for APTT
measurements. APTT kits (HemosIL, Lexington, MA) were used as per the manufacturers
instructions.
5.2.9 Statistics
All statistical tests were performed on R, version 3.0.1. Student's t test was utilized for all
data, with p<0.05 denoting statistical significance. The Pearson's product-moment correlation
test was utilized to determine the relationship between NP accumulation and carotid occlusion
time. Error bars represent standard error of the mean.
5.2.10 Study Approval
All animal experimental procedures were performed with approval from the Washington
University Animal Studies Committee.
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5.3 Results
5.3.1 Anti-thrombin Nanoparticles Reduce Vascular Procoagulant Activity in vivo
To characterize the effects of PPACK-NP on reducing procoagulant activity, groups of
ApoE-null mice were fed a Western diet for 3 months followed by continuation of the diet with
treatment (saline, control NP, and PPACK-NP) for 1 additional month. At the conclusion of the
treatment/feeding period, mice were subjected to a previously validated11,18,19 model for
measuring thrombotic risk using photochemical injury of the carotid artery that yields a
quantitative metric of coagulant activity (vessel occlusion time) with good dynamic range and
monotonic responsiveness to therapeutic agents that affect clotting. Prior to performing the
vessel injury, mice were maintained on their diets for 2-3 additional days without further
treatment to allow washout of any residual anti-thrombin nanoparticles. After 1 month of
PPACK-NP treatment, carotid occlusion times increased significantly over control groups (Fig.
5-2A), with occlusion times reaching 48.71 ± 6.7 min (N=7) compared to saline treatment (26.11
± 4.63 min, N=9, p=0.005) and control NP treatment (25.55 ± 4.17 min, N=9, p=0.004). We note
that the occlusion times in the 1-month PPACK-NP treated group approximated those of
previously reported fat-fed ApoE null mice after 2 months off diet, indicating that the PPACK
NP therapy may more rapidly attenuate vessel procoagulant activity than does dietary
management in this model, despite maintenance of the high fat diet in the PPACK NP treated
group.11
5.3.2 Anti-thrombin Nanoparticles Restore Vascular Barrier Integrity in vivo
We tested the ability of PPACK-NP treatment to restore functional endothelial barriers,
which concomitantly might be expected to reduce plaque procoagulant activity as previously
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reported.11 Mice were injected with a dose of CE-NP for MR spectroscopy that were allowed to
circulate for 2 hours prior to sacrifice, at which time plaque saturation occurs.10 Following this
circulation time, the entire length of the aorta (from the aortic root to the bifurcation) was
removed for ex vivo 19F-MRS measurements at 11.7T. Figure 5-2B illustrates the beneficial
effects of PPACK-NP treatment for 1 month on plaque endothelial permeability according to the
decreased deposition of CE-NP (0.084 ± 0.009 µl/g aorta, N=7) compared to saline (0.122 ±
0.011 µl/g aorta, N=8, p=0.023) and control NP (0.132 ± 0.013 µl/g aorta, N=10, p=0.014).
Using paired samples, we observed an inverse correlation (R = -0.56, Fig. 5-2C) between plaque
permeability and vessel procoagulant activity (p=0.004), consistent with our previous
observation that thrombotic risk tracks with plaque permeability to PFC-NP.11
A subset of mice was allocated for measurements of plaque extent in the aortic arch by
conventional Sudan IV staining and computer assisted planimetry.20 Overall, PPACK-NP
treatment resulted in a 22.5% decrease in aortic arch plaque extent (Fig. 5-2D): 40.24 ± 3.21%
plaque area for saline-treated mice (N=5) and 31.91 ± 1.69% plaque area for PPACK-NP treated
mice (N=7, p=0.03).
5.3.3 Anti-thrombin Nanoparticles Attenuate Inflammatory Signaling Molecules
PAR-1 responses: To delineate molecular signaling events responsible for the beneficial
effects of PPACK-NP, cell culture studies were used to quantify the responses of activated
endothelial and monocytic cell lines to thrombin inhibition. First, as thrombin's effect on cell
types is mediated primarily by cleavage of the PAR-1 receptor on cell surfaces5, flow cytometry
was used to determine the percentage of intact PAR-1 receptors that was left after treatment with
thrombin in the various treatment groups. PPACK-NP treatment completely prevented thrombin
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cleavage of PAR-1 receptors on human aortic endothelial cells (HAECs), compared to thrombin
or thrombin/control NP groups, which manifested significantly decreased PAR-1 expression
(N=3 for both groups, p=0.019 and p=0.000005, respectively) as compared to baseline (Fig. 53A).
Tissue Factor responses: Because PPACK-NPs successfully prevented PAR-1 activation,
we tested the downstream signaling effects of PAR-1 activation related to inflammation and
coagulation. Expression of tissue factor on the surface of HAECs and THP-1 monocytes in
response to thrombin stimulation was assayed using a functional assay of measuring FXa
generation as a result of the presence of TF/FVIIa complexes. PPACK-NP prevented thrombininduced TF expression on the surface of both HAECs (Fig. 5-3B) and THP-1 monocytes (Fig. 53C), with no significant increase over baseline TF levels at both concentrations of thrombin
utilized (1 U/ml and 4 U/ml). Whole excised aortic arch segments exhibited a marked reduction
in TF-positive plaque area after PPACK-NP treatment: 46.75 ± 5.74% (N=3) in PPACK treated
mice (Fig. 3D), versus 72.69 ± 5.06% (N=3, p=0.027) for saline treatment and 72.52 ± 4.34%
(N=3, p=0.023) for control NP treatment as quantified in immunofluorescent staining using
ImageJ (Fig. 5-3E-G).
NFkB responses: Because thrombin is known to stimulate NFkB transcriptional
regulation of a panoply of inflammatory genes through PAR-1 signaling, we delineated the effect
of PPACK-NP on the inhibition of NF-kB activation in HAEC (Fig. 5-4A-E) and THP-1 cells
(Fig. 5-4F-J). Thrombin cleavage of PAR-1 results in the activation of Gαq and dissociation of
the Gβγ complex, which subsequently results in the parallel activation of PKCσ and PI3kinase/Akt pathways. These parallel pathways then converge to stimulate IKK, which results in
the binding of the p65 homodimer to IκB and subsequent phosphorylation and degradation of
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IκB. Activation of the PKCσ pathway results in activation of p38 which in turn, phosphorylates
p65 to induce the nuclear translocation and transcriptional activity of the p65.21
Cell cultures were stained for phosphorylated p65 following six hours of thrombin
stimulation and treatment. Treatment with PPACK-NP resulted in little to no observable positive
staining for intracellular phospho-p65 and preservation of IkB protein (Fig. 5-5) compared to
thrombin and thrombin/control NP treatment groups. The preservation of IkB indicates that this
cytoplasmic regulatory component of p65/p50 retains control of the preexisting cytoplasmic
stores of p65 thereby preventing subsequent p65 phosphorylation and translocation to the
nucleus.
Next we quantified pp65 in the endothelium (Fig. 5-6A) and intraplaque regions (Fig. 56B), by staining sections of the excised aortic arch for phosphorylated NF-kB p65 (pp65, Fig. 56C-E), where increased phosphorylation of p65 indicates increased NF-kB activity. After
PPACK-NP treatment, aortic plaques exhibited significantly decreased endothelial pp65 (11.49 ±
3.66%, N=3) compared to saline (33.11 ± 4.05%, N=3, p=0.017) and control NP treatments
(33.25 ± 4.33%, N=3, p=0.019). Decreased macrophage pp65 also was observed in plaque
regions after PPACK-NP treatment (21.78 ± 3.15%, N=3) compared to saline (43.31 ± 6.55%,
N=3) and control NP treatments (47.51 ± 4.59%, N=3). To rule out loss of endothelial pp65
staining due to missing endothelium, selected neighboring slide sections where pp65 was noted
to be reduced were stained for vWF, indicating that endothelium was present, thus confirming
the specificity for NFkB downregulation by PPACK-NP in endothelium in vivo (Fig. 5-6F-H).
Systemic coagulation and inflammation markers: Thrombin-antithrombin (TAT)
complexes are correlative systemic harbingers of procoagulant activity.22 PPACK-NP treatment
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significantly reduced serum thrombin-antithrombin (TAT) complexes (5.43 ± 0.64 ng/ml, N=5;
p=0.0001 vs. saline, p=0.032 vs control NP) (Fig. 5-7A) versus saline (13.32 ± 1.01 ng/ml, N=6)
and control NP (9.96 ± 1.64 ng/ml, N=5, p=NS vs. saline).
Because NF-kB is a known driver of endothelial adhesion molecules, we measured
soluble VCAM-1 (sVCAM-1) levels as biomarkers of activated endothelium in atherosclerosis.23
ELISA analysis of sVCAM-1 (Fig. 5-7B) revealed a modest, but significant decrease in
sVCAM-1 with PPACK-NP treatment (1504.88 ± 65.25 ng/ml, N=4) compared to saline
treatment (1666.37 ± 12.78 ng/ml, N=5, p=0.029)
Macrophage responses: Excised aortic arch sections were stained for macrophages (Fig.
5-8A-C) and plaque macrophage content was quantified using ImageJ. We observed no
significant difference between treatment groups in terms of overall plaque macrophage content
(Fig. 5-8D).
Systemic responses to PPACK-NP: APTT measurements conducted on serum collected
at the time of sacrifice indicated no persistent non-specific effects of PPACK-NP after the
terminal treatment dose 2-3 days prior to sacrifice (Fig. 5-8E). Furthermore, no significant
difference was observed in serum cholesterol following the PPACK-NP treatment regimen (Fig.
5-8F).
5.4 Discussion
The principal new observation in this work is that focal inhibition of plaque thrombin in
fat-fed ApoE-null mice results in rapid recovery of damaged endothelial barriers and attenuated
vascular procoagulant activity in spite of a continued Western diet. These beneficial outcomes
were achieved with the use of anti-thrombin nanoparticles that passively permeated plaque
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intimal regions after i.v. injection and were focally retained to exert sustained pleiotropic antiinflammatory effects. Additionally, the progression of atherosclerotic plaque in lesion-prone
areas of the ascending aorta was forestalled during the 1 month treatment period. Potential
mechanisms for promoting quiescence in activated endothelium related to downregulation of
inflammatory NFkB signaling activity through inhibition of the thrombin-PAR1 signaling are
illustrated in Fig. 5-9.
The direct relationship between thrombotic risk and endothelial barrier disruption (Fig. 52C and Fig. 4-3 in Chapter 4) according to the metrics employed in these models confirms a
primary role for intact endothelium in maintaining vascular homeostasis in atherosclerosis.
Recent reports of the relationship between endothelial damage/sloughing and acute coronary
syndromes in patients24 recalls original descriptions of hypercoagulable vascular erosions by the
Virmani group25 and focuses attention on ways to measure and preserve endothelial integrity as a
strategic path to the detection and reduction of thrombotic risk. Prior work in our lab indicates
that the effects of cholesterol feeding elicit both procoagulant effects and barrier disruption only
after some time on a sustained high fat diet: >3 months in ApoE-null mice11 and >6 months in
NZW rabbits10). In ApoE-null mice, barrier disruption worsens progressively over time on a
high fat diet, but can resolve rapidly within 2 months after switching to normal chow.11 Although
leaky vasculature and reduced vasodilatory capacity associated with endothelial dysfunction may
occur within weeks of inception of an atherogenic diet in the ApoE-null model26, the barrier
disruption and procoagulant activity identified by our nanoparticle permeability metrics emerge
later and may serve as more direct harbingers of thrombotic risk.
With respect to the underlying mechanisms responsible for endothelial damage,
inflammatory signaling and immunomodulatory events orchestrated by various plaque cell types
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interacting with activated endothelium have been described in detail.6 Here we have focused on
thrombin as a key instigator of plaque growth and instability contributing to endothelial
activation, vessel inflammation, and hypercoagulability, as summarized in Figure 5-9
Surprisingly, after an aggressive one-month treatment period with PPACK-NP following 3
months of initial cholesterol feeding, marked benefits were observed even in the face of
persistently elevated serum cholesterol. The role of thrombin not only as a principal
prothrombotic agent, but also as an atherogenic molecule is not unexpected given that it drives
many of the inflammatory molecules that participate in plaque growth such as NFkB21, NADPH
oxidase27, VCAM-128, PDGF29, among many others.6 Thrombin's role as a proinflammatory
molecule through the activation of the NF-kB pathway results in numerous downstream effects
that accelerate plaque development, cell infiltration, expression of inflammatory molecules, and
promotion of hypercoagulability through stimulation and secretion of procoagulant enzymes.30
Of particular interest is the role of endothelial-specific NFkB activation in atherogenesis
as demonstrated by Gareus et al. with the use of genetically engineered conditional knockouts of
endothelial NFkB that markedly suppressed plaque formation in fat-fed ApoE-/- mice.31 The
seminal observations of very early upregulation of NFkB in lesion prone aortic arch regions by
Cybulsky’s group32 raises the interesting speculation of a role for thrombin even at these
incipient time points, particularly in the context of previously documented clusters of intense,
albeit small, clusters of endothelial apoptosis and replication in these aortic arch regions even in
normal subjects.33,34 The ability to achieve focal suppression of NFkB with nanoparticle delivery
systems that might abrogate endothelial PAR-1 activation could help to maintain a more
quiescent endothelial phenotype (e.g., reduced sVCAM: Fig 5-7B), preserve barrier integrity,
and simultaneously reduce paracrine crosstalk with other inflammatory plaque components.
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A pleiotropic response to the suppression of thrombin signaling in diverse cell types that
participate in atherogenesis is evidenced by modulation of NFkB in THP-1 as well as HAEC
cells (Fig. 5-4A-J, and Fig. 5-5), and our previous reports of reduced platelet content in clots that
are produced by vessel injury.12,13 Regarding platelet activation, synergistic benefits also could
accrue by local inhibition of thrombin-PAR-1 signaling through the NFkB axis.35 However, as a
potential caveat, it is interesting to note that selective inhibition of NFkB in macrophage
populations has been associated with increased atherosclerosis as contrasted with more specific
inhibition of endothelial NFkB.36 Although we show that NFkB may be downregulated in
representative human monocyte cell lines in vitro by interrupting thrombin/PAR-1 activation
(Fig. 5-3A) and in vivo through quantification of pp65 staining in PPACK-NP treated mice, the
exact relationships between macrophages and endothelial signaling and responses to this
intervention remain to be defined.
Recent experimental reports have explored the role of thrombin and related coagulation
enzymes in promoting atherosclerosis with the use of orally administered antithrombotic agents
or genetically modified mice for primary prevention of atherosclerosis.37-39 All such studies
report significant decreases in overall plaque extent and reduced expression of inflammatory
mediators. Secondary prevention clinical trials in patients with acute coronary syndromes using
oral anti-thrombotic agents have shown very modest effects on subsequent clinical events related
to atherosclerosis progression, but at the risk of significantly increased bleeding.9 Interestingly,
nanoparticle-based thrombin inhibition exhibits similar therapeutic effects to that of the
experimental studies mentioned above, but with significantly fewer treatments (12 doses over 4
weeks), no requirement for cholesterol reduction (Fig. 5-8F), and a more promising safety profile
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as coagulation parameters and bleeding times have been shown to normalize within 30-60
minutes after i.v. injection.12
We observed no significant change in plaque macrophage content between treatment
groups (Fig. 5-8A-D) in contrast to the 50% decrease in plaque macrophages reported by Hara et
al. after 5 months of Xa inhibition.40 However, despite our shorter 1-month time window of
therapeutic intervention that may not have allowed for reduced plaque macrophage content, our
observations of rapid downregulation of NF-kB and downstream inflammatory markers (TF,
TAT complexes, sVCAM) (Fig. 5-6C-E), is consistent with the similar observations of Kadoglou
et al in dabigatran-treated ApoE-null mice.38 These results also accord with previously published
data41 demonstrating the effect of thrombin and PPACK-thrombin in modulating the expression
of TF in human saphenous vein endothelial cells, which is thought to be due to activation of NFkB.
The optimal dosing interval for this therapy and the duration of the local effect on barrier
integrity and procoagulant activity remain to be defined. PPACK-NP exhibit a mean clearance
half-life of 105.87 ± 23.38 min, compared to clearance half-lives for plain PFC-NP (181.3 ± 40.7
min) and PEGylated PFC-NP (240.16 ± 23.42 min), indicative of only modest effects on
pharmacokinetics with selected particle surface modifications. The anticipated clearance
mechanism for PFC-NP was the reticuloendothelial system as demonstrated by 19F-MR imaging
of mice post-mortem, which depicted accumulation of nanoparticles in the liver and spleen
following 2 hours of nanoparticle circulation prior to sacrifice.42 This minor difference in PK
may allow for convenient swapping of alternative anticoagulants such as bivalirudin as we have
shown previously.13 These PK parameters are advantageous for potential clinical applications, as
we have previously shown in mice that nanoparticle clearance through the RES results in
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reduction of residual circulating (i.e., nontrapped) bioactive conjugated PPACK or bivalirudin
moieties within 30-60 minutes to a level below that required to alter systemic clotting and
bleeding parameters.12,13 The potential disadvantage of intravenous nanotherapy also is notable,
but there are a number of clinical scenarios that might benefit from early and aggressive
treatment for a period of time before effective cholesterol control could be established. It is also
important to note that the particular thrombin inhibitor PPACK may not be entirely specific to
thrombin as a serine protease inhibitor, and that local inhibition of other coagulation proteases
(e.g. Xa) may in fact exert a synergistic but still locally constrained effect in preventing the
activation of thrombin.
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Figure 5-1

Figure 5-1: (A) Schematic of PPACK-NP (center panel). Nanoparticles consist of a
perfluorocarbon core surrounded by a stabilizing phospholipid monolayer to which PPACK is
covalently conjugated. In this work, PPACK-NP act on both the exterior and interior regions of
plaques in inhibiting the inflammatory effects of thrombin. Fluorescent microscopy image (right
panel) of mouse atherosclerotic plaque at 3 months of cholesterol feeding demonstrates
intraplaque accumulation of PPACK-NP (red). Sudan IV staining of the aortic arch of cholesterol
fed ApoE mice demonstrates ample plaque deposition serving as a target for PPACK-NP therapy
(left panel) (B) Feeding and dosing schedule for ApoE-null mice. During the 4-week treatment
period, mice received i.v. treatments three times per week. (C) Schematic representation of 19FMRS-based detection of endothelial barrier disruption. Non-targeted CE-NP are administered
and circulated for 2 hours. Aortas are removed and 19F signal is measured. High 19F signal
corresponds to increased endothelial barrier disruption and increased nanoparticle accumulation,
where as low 19F signal corresponds to decreased endothelial barrier disruption and diminished
nanoparticle accumulation. (D) Representative kinetics of photochemically-induced thrombus
formation in ApoE-null mice treated with either saline, control NP or PPACK-NP.
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Figure 5-2

Figure 5-2: (A) PPACK-NP treatment (rightmost bar) significantly increases time to occlusion of
the carotid artery by 46% over saline (p=0.005) and control NP (p=0.004) treatments. (B) Plaque
permeability is reduced with PPACK-NP treatment by 33% compared to saline (p=0.023) and
control NP treatments (p=0.014). (C) Paired samples of aortic nanoparticle accumulation
measurements and carotid occlusion times demonstrates a significant inverse correlation between
the two metrics, confirming prior work indicating a relationship between increased endothelial
permeability and increased vessel hypercoagulability. (D) Sudan IV staining of the aortic arch of
saline and PPACK-NP treated mice demonstrates a 22.5% decrease in gross plaque deposition
with PPACK-NP treatment vs. saline treatment (p=0.03) as quantified with ImageJ.
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Figure 5-3

Figure 5-3: (A) Flow cytometry for intact PAR-1 receptors following thrombin stimulation in the
presence of each treatment group demonstrates inhibition of thrombin-mediated cleavage of
PAR-1 with PPACK-NP treatment. (B) PPACK-NP inhibit expression of surface tissue factor on
HAECs and (C) THP-1 cells in response to stimulation with different concentrations of thrombin
(light gray bars, 1U/ml; dark gray bars, 4U/ml). **p<0.005, ***p<0.0005 (D) diminished tissue
factor expression in PPACK-NP treated-mice (p=0.027 and 0.023 vs saline and control NP,
respectively) as quantified by ImageJ. (E-G) Immunofluorescent staining of tissue factor in
ApoE-null mice treated with (E) saline, (F) control NP, and (G) PPACK-NP.
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Figure 5-4

Figure 5-4: Immunocytochemistry for phosphorylated p65 demonstrates inhibition of NF-κB
activation in (A-E) HAECs and (F-J) THP-1 cells with PPACK-NP treatment.
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Figure 5-5

Figure 5-5: Immunocytochemistry for IkB on HAECs demonstrates diminished degradation of
IkB in response to thrombin stimulation with PPACK-NP treatment, consistent with inhibited
activation of NF-kB.
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Figure 5-6

Figure 5-6: ImageJ quantification of (A) endothelial and (B) intraplaque phospho-p65 staining
on (C-E) ApoE-null mouse plaques demonstrate significantly less endothelial and macrophage
phospho-p65. (F-H) Von Willebrand factor staining was conducted on neighboring sections to
rule out loss of endothelial phospho-p65 staining due to missing endothelium in this case.
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Figure 5-7

Figure 5-7: (A) ELISA evaluation of thrombin-antithrombin complexes reveals a significant
decrease in detected TAT-complexes following one month of PPACK-NP treatment. (B) ELISA
analysis for detection of serum soluble VCAM-1 (sVCAM-1) demonstrated a decrease in
detectable sVCAM-1 following one month of PPACK-NP treatment.
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Figure 5-8

Figure 5-8: Immunofluorescent staining for macrophages in ApoE-null mouse plaques treated
with (A) saline, (B) control NP, and (C) PPACK-NP revealed no significant difference in (D)
detected plaque macrophages as quantified with ImageJ. (E) No significant difference in
activated partial thromboplastin time (APTT) between treatment groups indicating no persisting
systemic effect of PPACK-NP on coagulation 2-3 days after the penultimate treatment dose. (F)
No significant difference was observed on serum cholesterol between treatment groups,
indicating that therapeutic effects observed occurred without cholesterol lowering as a
consequence of nanoparticle treatment.
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Figure 5-9

Figure 5-9: Schematic depiction of the effect of PPACK-NP on reducing the inflammatory
effects of thrombin. Thrombin promotes the release of inflammatory molecules (cell adhesion
molecules) and procoagulant molecules (TAT complexes, tissue factor) as demonstrated in this
work, through the activation of the NF-κB pathway as measured through IκB degradation and
phosphorylation of p65.
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Chapter 6: Conclusions
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The work described in this dissertation confirms the role of thrombin as a potent mediator
of inflammation that drives the progression of atherosclerosis as a key factor in the disruption of
endothelial barrier integrity. Several groups have noted the importance of thrombin and the role
it plays in early plaque development either through genetic knockout studies of thrombomodulin1
or through various studies involving the use of orally administered anticoagulants during the
course of atherosclerotic development in ApoE-/- mice.2-4.
In Chapter 2, we investigated the utility of nanoparticles (specifically liposomes) as
thrombin inhibitors through the surface conjugation of the direct thrombin inhibitor Dphenylalanyl-L-prolyl-L-arginyl chloromethylketone (PPACK) as a means to delay clot
formation without exerting significant systemic anticoagulant effects, which has been described
as a "holy grail" for antithrombotic drug development.5We demonstrated in this work that these
nanoparticulate inhibitors of thrombin manifest high-localized antithrombotic activity at the site
of injury, with rapid normalization of systemic anticoagulation parameters (APTT, tail vein
bleeding time) after an initial bolus. A key observation in this work is the propensity of
nanoparticle-based thrombin inhibitors to bind to areas of active thrombosis to form an "anticlotting surface" that prevents or delays the formation of additional clot. We observed that this
interaction was due in part to interactions of PPACK on the surface of the liposome with
thrombin bound to the surface of clots, which is a population of active thrombin that heparin is
largely unable to inhibit. Due to the presence of multiple copies of PPACK (6254.24 ±

1245.14 copies per liposome, ~13650 PPACK per perfluorocarbon nanoparticle6) on the
nanoparticle/liposome surface, a particle that binds to the surface of the clot exposes PPACK to
the periphery of the clot, thus preventing the actions of free thrombin at the site of injury.
In Chapter 3, we expanded on the concept of generation anticlotting surfaces with
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antithrombin nanoparticles by applying nanoparticles to the surface of thrombin-coated stents to
prevent clot deposition upon exposure to plasma. The results of this work demonstrate a novel
role for thrombin-inhibiting nanoparticles as inhibitors of thrombosis on vascular devices.
Thrombosis is a significant factor in the failure of vascular devices and implants, requiring that
patients be maintained on continuous anticoagulation for some time after implantation, leaving
them at risk for hemorrhage. Indeed, recent clinical studies have recommended increasing time
on dual antiplatelet therapy, underlining the importance of developing alternative methods for
preventing thrombosis of vascular implants. The results of our work demonstrate that stent
thrombosis might be prevented with the use of thrombin-inhibiting nanoparticles. However it is
important to note several limitations of this study. All experiments were carried out using in vitro
models, where the in vivo effects of PPACK-NP on stent thrombosis are not yet known. Future
work aims to address the in vivo effect of PPACK-NP, however we hypothesize that PPACK-NP
treatment could be efficacious based on prior work done on acute models of thrombosis
demonstrated in Chapter 2 and in prior work in our lab by Myerson et al.6,7
In Chapter 4, we elucidated the relationship between thrombosis/hypercoagulability as it
relates to the integrity of the endothelium. Fluorine magnetic resonance spectroscopy (19F-MRS),
was used to detect progressive changes in the permeability of ApoE-/- mouse vascular barriers to
200 nm diameter perfluorocarbon nanoparticles, where increasing passive permeation and
retention of nanoparticles was observed as a function of time on a high cholesterol diet.
Interestingly, we were able to detect the ability of plaques to "heal" upon removal of an
inflammatory stimulus (in this case, dietary cholesterol), according to the observed reduction of
nanoparticle depostion in plaques following dietary management. Furthermore, we observed that
increased nanoparticle retention in the aorta due to endothelial barrier disruption was correlated
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inversely with vessel procoagulant activity, or the time to thrombotic occlusion of the carotid
artery after dye-laser injury. This relationship suggests a direct, quantitative and causal link
between endothelial damage and propensity for thrombosis. These results are translationally
applicable to a current unmet need for novel techniques that can accurately classify plaques at
risk of thrombosis, as current noninvasive diagnostic imaging methods are unable to detect the
presence of plaque erosions8, which represent over 1/3 of all acutely thrombosed lesions9, and
can only be diagnosed post-mortem.
Finally, in Chapter 5, we demonstrated the therapeutic utility of focal thrombin inhibition
with anti-thrombin nanoparticles for preserving endothelial barrier integrity as a consequence of
modulating hypercoagulability and vascular inflammation. Furthermore, we were able to assess
the extent of endothelial barrier disruption as measured non-invasively with fluorine (19F)
magnetic resonance spectroscopy as described in Chapter 4. This work demonstrates a
significant role for nanoparticle-based treatments in forestalling the progression of
atherosclerosis simply by inhibiting a fundamental inciting molecule, thrombin. This intervention
results in a significant downstream decrease in NF-kB activity in plaques, that is associated with
decreased hypercoagulability and restoration of vascular barrier integrity. Interestingly, the
content of plaque macrophages remained unchanged irrespective of treatment, at least over this
short interval, indicating that the early effects of thrombin inhibition operate by suppressing the
activity of macrophages rather than by depleting their numbers to elicit the beneficial effects on
plaque growth. Moreover, the results are obtained in the face of continued high blood levels of
cholesterol, indicative of the critical role of thrombin in driving inflammation and plaque growth.
Future work might focus on longer term intervention to examine the response of macrophage
populations with respect to mechanistic efferocytosis, cellular egress, and actual plaque burden
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reduction. Taken together, these results clearly establish a prominent role for thrombin in the
very early inflammatory events that promote plaque growth and not just in the later emergence of
plaque instability and thrombosis that is the current dogma.
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